

SECURITIES NOTE



TARGOVAX ASA

(A public limited company incorporated under the laws of Norway)

Rights Issue and listing on the Oslo Stock Exchange of 101,744,186 Offer Shares at a Subscription Price of NOK 1.72 per Offer Share with Subscription Rights for Existing Shareholders

Subscription Period for the Rights Issue: From 09:00 hours (CET) on 30 November 2021 to 16:30 hours (CET) on 14 December 2021

Trading in Subscription Rights: From 09:00 hours (CET) on 30 November 2021 to 16:30 hours (CET) on 10 December 2021

This Securities Note (the "**Securities Note**") has been prepared in connection with the rights issue (the "**Rights Issue**") and listing by Targovax ASA (the "**Company**"), a public limited company incorporated under the laws of Norway (together with its consolidated subsidiaries, "**Targovax**" or the "**Group**") on Oslo Børs, a stock exchange operated by Oslo Børs ASA (the "**Oslo Stock Exchange**") of 101,744,186 new shares in the Company, each with a par value of NOK 0.10 (the "**Offer Shares**") to be issued at a subscription price of NOK 1.72 per Offer Share (the "**Subscription Price**"). The Company will through the Rights Issue raise gross proceeds of approximately NOK 175,000,000.

The shareholders of the Company as of 25 November 2021 (and being registered as such in the Norwegian Central Securities Depository (the "**VPS**") as at the expiry of 29 November 2021, pursuant to the two days' settlement procedure of VPS (the "**Record Date**")) (the "**Existing Shareholders**"), will be granted subscription rights (the "**Subscription Rights**") in the Rights Issue that, subject to applicable law, provide preferential rights to subscribe for, and be allocated, Offer Shares at the Subscription Price. The Subscription Rights will be registered on each Existing Shareholder's VPS account. The Subscription Rights will be listed and tradable on the Oslo Stock Exchange from 09:00 hours Central European Time ("**CET**") on 30 November 2021 to 16:30 hours (CET) on 10 December 2021 under the ticker code "TRVXT".

Each Existing Shareholder will be granted 1.175114 Subscription Rights for each existing share registered as held by such Existing Shareholder as of the Record Date, rounded down to the nearest whole Subscription Right. Subscription Rights acquired during the trading period for the Subscription Rights as set out above carry the same right to subscription as the Subscription Rights held by Existing Shareholders. Each Subscription Right will, subject to applicable law, give the right to subscribe for, and be allocated, one (1) Offer Share. Over-subscription and subscription without Subscription Rights is permitted. The subscription period will commence at 09:00 hours (CET) on 30 November 2021 and expire at 16:30 hours CET on 14 December 2021 (the "**Subscription Period**").

SUBSCRIPTION RIGHTS THAT ARE NOT USED TO SUBSCRIBE FOR OFFER SHARES BEFORE THE EXPIRY OF THE SUBSCRIPTION PERIOD OR SOLD BEFORE 16:30 HOURS (CET) ON 10 DECEMBER 2021 WILL HAVE NO VALUE AND WILL LAPSE WITHOUT COMPENSATION TO THE HOLDER.

Following expiry of the Subscription Period, any Offer Shares that have not been subscribed for and allocated in the Rights Issue will be subscribed and paid for at the Subscription Price by certain existing shareholders of the Company and new investors as described in Section 11.23 "The Underwriting" (collectively, the "**Underwriters**"), subject to the terms and conditions of the underwriting agreement entered into between the Company and the Underwriters dated 3 November 2021 (the "**Underwriting Agreement**").

The Company's existing shares are, and the Offer Shares will be, listed on the Oslo Stock Exchange under the ticker code "TRVX". Except where the context otherwise requires, references in this Securities Note to "**Shares**" will be deemed to include the existing shares in the Company and the Offer Shares.

All of the existing Shares are, and the Offer Shares will be, registered in the VPS in book-entry form. All of the issued Shares rank pari passu with one another and each carries one vote.

Investing in the Subscription Rights or the Shares, including the Offer Shares, involves a high degree of risk. Prospective investors should read the entire document together with the registration document dated 29 November 2021 published by the Company (the "Registration Document") and, in particular, consider Section 2 "Risk Factors" herein beginning on page 10 and Section 1 "Risk Factors" of the Registration Document beginning on page 3 therein when considering an investment in the Company.

The Subscription Rights and the Offer Shares are being offered only in those jurisdictions in which, and only to those persons to whom, offers and sales of the Offer Shares and Subscription Rights may lawfully be made and, for jurisdictions other than Norway, would not require any filing, registration or similar action.

The Subscription Rights and the Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or with any securities regulatory authority of any state or other jurisdiction in the United States, and are being offered and sold: (i) in the United States only to "qualified institutional buyers" ("QIBs") as defined in Rule 144A under the U.S. Securities Act ("Rule 144A") in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions" as defined in, and in compliance with, Regulation S under the U.S. Securities Act ("Regulation S"). The distribution of this Securities Note and the offer and sale of the Subscription Rights and the Offer Shares in certain jurisdictions may be restricted by law.

For more information regarding restrictions in relation to the Rights Issue, see Section 12 "Selling and Transfer Restrictions".

The due date for the payment of the Offer Shares is expected to be on or about 17 December 2021. Delivery of the Offer Shares is expected to take place on or about 22 December 2021 through the facilities of the VPS. Trading in the Offer Shares on the Oslo Stock Exchange is expected to commence on or about 22 December 2021.

Managers

Carnegie AS

DNB Markets, a part of DNB Bank ASA

The date of this Securities Note is 29 November 2021

IMPORTANT INFORMATION

This Securities Note has been prepared in connection with the Rights Issue and the listing of the Offer Shares on the Oslo Stock Exchange.

This Securities Note has been prepared to comply with the Norwegian Securities Trading Act of 29 June 2007 no. 75 (the "**Norwegian Securities Trading Act**") and related secondary legislation, including Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2014/17/EC, as amended, and as implemented in Norway in accordance with section 7-1 of the Norwegian Securities Trading Act (the "**EU Prospectus Regulation**"). This Securities Note has been prepared solely in the English language. This Securities Note has been approved by the Financial Supervisory Authority of Norway (Nw.: *Finanstilsynet*) (the "**Norwegian FSA**"), as competent authority under the EU Prospectus Regulation. The Norwegian FSA only approves this Securities Note as meeting the standards of completeness, comprehensibility and consistency imposed by the EU Prospectus Regulation, and such approval should not be considered as an endorsement of the issuer or the quality of the securities that are the subject of this Securities Note. Investors should make their own assessment as to the suitability of investing in the securities. The Securities Note has been prepared in accordance with the simplified disclosure regime for secondary issuances.

For definitions and certain other terms used throughout this Securities Note, see Section 13 "Definitions and Glossary".

The Company has engaged Carnegie AS and DNB Markets, a part of DNB Bank ASA, as managers for the Rights Issue (the "**Managers**").

The information contained herein is current as at the date hereof and is subject to change, completion and amendment without notice. In accordance with Article 23 of the EU Prospectus Regulation, significant new factors, material mistakes or material inaccuracies relating to the information included in this Securities Note, which may affect the assessment of an investor and which arises or is noted between the time when the Securities Note is approved by the Norwegian FSA and the listing of the Offer Shares on the Oslo Stock Exchange, will be mentioned in a supplement to this Securities Note without undue delay. Neither the publication nor distribution of this Securities Note, or the sale of any Offer Share, shall under any circumstances imply that there has been no change in the Group's affairs or that the information herein is correct as at any date subsequent to the date of this Securities Note.

No person is authorized to give information or to make any representation concerning the Group or in connection with the Rights Issue or the sale of the Offer Shares or the Subscription Rights other than as contained in this Securities Note. If any such information is given or made, it must not be relied upon as having been authorized by the Company or the Managers or by any of the affiliates, representatives, advisors or selling agents of any of the foregoing.

The distribution of this Securities Note and the offer and sale of the Offer Shares and grant or use of the Subscription Rights in certain jurisdictions may be restricted by law. This Securities Note does not constitute an offer of, or an invitation to purchase, any of the Offer Shares or use the Subscription Rights to subscribe for Offer Shares in any jurisdiction in which such offer, sale or subscription would be unlawful. Neither this Securities Note nor any advertisement or any other offering material may be distributed or published in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations. Persons in possession of this Securities Note are required to inform themselves about, and to observe, any such restrictions. In addition, the Shares and the Subscription Rights are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under applicable securities laws and regulations. Investors should be aware that they may be required to bear the financial risks of this investment for an indefinite period of time. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. For further information on the sale and transfer restrictions of the Subscription Rights and the Offer Shares, see Section 12 "Selling and Transfer Restrictions".

Any reproduction or distribution of this Securities Note, in whole or in part, and any disclosure of its contents is prohibited.

This Securities Note and the terms and conditions of the Rights Issue as set out herein, and any sale and purchase of Offer Shares and the granting and use of the Subscription Rights hereunder, shall be governed by and construed in accordance with Norwegian law. The courts of Norway, with Oslo as legal venue, shall have exclusive jurisdiction to settle any dispute which may arise out of or in connection with the Rights Issue or this Securities Note.

In making an investment decision, prospective investors must rely on their own examination, and analysis of, and enquiry into the Group and the terms of the Rights Issue, including the merits and risks involved. Neither the Company nor the Managers, or any of their respective representatives or advisors, are making any representation to any investor in the Offer Shares or holder of Subscription Rights regarding the legality of an investment in the Offer Shares or the Subscription Rights by such investor under the laws applicable to such investor. Each reader of this Securities Note should consult with his or her advisors as to the legal, tax, business, financial and related aspects of a purchase of the Offer Shares or the use of the Subscription Rights to subscribe for Offer Shares.

All Sections of the Securities Note should be read in context with the information included in Section 4 "General Information".

Investing in the Shares involves certain risks. See Section 2 "Risk Factors" beginning on page 10.

NOTICE TO INVESTORS IN THE UNITED STATES

Because of the following restrictions, prospective investors are advised to consult legal counsel prior to making any offer, resale, pledge or other transfer of the Offer Shares or the Subscription Rights. The Offer Shares and the Subscription Rights have not been and will not be registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction in the United States and may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. All offers and sales in the United States will be made only to QIBs in reliance on Rule 144A or pursuant to another exemption from, or in transactions not subject to, the registration requirements of the U.S. Securities Act. All offers and sales outside the United States will be made in "offshore transactions" as defined in, and in reliance on, Regulation S. Prospective purchasers are hereby notified that sellers of Offer Shares or Subscription Rights may be relying on the exemption from the provisions of section 5 of the U.S. Securities Act provided by Rule 144A. See Section 12.2 "United States".

Any Offer Shares or Subscription Rights offered or sold in the United States will be subject to certain transfer restrictions and each purchaser will be deemed to have made acknowledgements, representations and agreements, as set forth under Section 12.2 "United States".

Neither the Offer Shares nor the Subscription Rights have been recommended by any United States federal or state securities commission or regulatory authority. Further, the foregoing authorities have not passed upon the merits of the Rights Issue or confirmed the accuracy or determined the adequacy of this Securities Note. Any representation to the contrary is a criminal offense under the laws of the United States.

In the United States, this Securities Note is being furnished on a confidential basis solely for the purposes of enabling a prospective investor to consider purchasing the Offer Shares or the Subscription Rights. The information contained in this Securities Note has been provided by the Company and other sources identified herein. Distribution of this Securities Note to any person other than the offeree specified by the Managers or their representatives, and those persons, if any, retained to advise such offeree with respect thereto, is unauthorized and any disclosure of its contents, without the prior written consent of the Company, is prohibited. This Securities Note is personal to each offeree and does not constitute an offer to any other person or to the public generally to purchase Offer Shares or Subscription Rights or subscribe for or otherwise acquire the Offer Shares or Subscription Rights.

To the extent that the Managers intend to effect any offers or sales of Shares in the United States or to U.S. persons, they will do so through their respective U.S. registered broker-dealer affiliates, pursuant to applicable U.S. securities laws.

NOTICE TO INVESTORS IN THE UNITED KINGDOM

Offers of Offer Shares are only being made to persons in the United Kingdom who are "qualified investors" within the meaning of section 86 of the Financial Services and Markets Act 2000 ("**FSMA**") or otherwise in circumstances which do not require publication by the Company of a prospectus pursuant to section 85(1) of the FSMA.

This Securities Note is only being distributed to and is only directed at (i) persons who are outside the United Kingdom (the "**UK**") or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "**Relevant Persons**"). The Subscription Rights and the Offer Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such rights or Shares will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this Securities Note or any of its contents.

The Managers have represented, warranted and agreed (i) that they have only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received by them in connection with the issue or sale of the Offer Shares and Subscription Rights in circumstances in which section 21(1) of the FSMA does not apply to the Company and (ii) that they have complied and will comply with all applicable provisions of the FSMA with respect to anything done by them in relation to the Offer Shares and the Subscription Rights in, from or otherwise involving the UK.

NOTICE TO INVESTORS IN THE EEA

In any member state of the European Economic Area (the "**EEA**") that has implemented the EU Prospectus Regulation, other than Norway (each, a "**Relevant Member State**"), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation. This Securities Note has been prepared on the basis that all offers of Subscription Rights and Offer Shares outside Norway will be made pursuant to an exemption under the EU Prospectus Regulation from the requirement to produce a prospectus for an offer of securities. Accordingly, any person making or intending to make any offer within the EEA of Offer Shares or Subscription Rights which is the subject of the Rights Issue contemplated in this Securities Note within any EEA member state (other than Norway) should only do so in circumstances in which no obligation arises for the Company or the Managers to publish a prospectus or a supplement to a prospectus under the EU Prospectus Regulation for such offer. Neither the Company nor the Managers have authorized, nor do they authorize, the making of any offer of Shares or Subscription Rights through any financial intermediary.

Each person in a Relevant Member State other than, in the case of paragraph (a), persons receiving offers contemplated in this Securities Note in Norway, who receives any communication in respect of, or who acquires any Offer Shares or Subscription Rights under, the offers contemplated in this Securities Note will be deemed to have represented, warranted and agreed to the Managers and the Company that:

- a) it is a qualified investor as defined in the EU Prospectus Regulation; and
- b) in the case of any Offer Shares or Subscription Rights acquired by it as a financial intermediary, as that term is used in Article 1 of the EU Prospectus Regulation, (i) such Offer Shares or Subscription Rights acquired by it in the Rights Issue have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than qualified investors, as that term is defined in the EU Prospectus Regulation, or in circumstances in which the prior consent of the Managers has been given to the offer or resale; or (ii) where such Offer Shares or Subscription Rights have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of those Offer Shares or Subscription Rights to it is not treated under the EU Prospectus Regulation as having been made to such persons.

For the purposes of this provision, the expression an "offer to the public" in relation to any of the Offer Shares and the Subscription Rights in any Relevant Member State means a communication to persons in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered, so as to enable an investor to decide to acquire any of the Offer Shares or Subscription Rights.

See Section 12 "Selling and Transfer Restrictions" for certain other notices to investors.

INFORMATION TO DISTRIBUTORS

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. Conversely, an investment in the Shares is not compatible with investors looking for full capital protection or full repayment of the amount invested or having no risk tolerance, or investors requiring a fully guaranteed income or fully predictable return profile.

The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

ENFORCEMENT OF CIVIL LIABILITIES

The Company is a public limited company incorporated under the laws of Norway. As a result, the rights of holders of the Shares will be governed by Norwegian law and the Company's articles of association (the "**Articles of Association**"). The rights of shareholders under Norwegian law may differ from the rights of shareholders of companies incorporated in other jurisdictions.

The members of the Company's board of directors (the "**Board Members**" and the "**Board of Directors**", respectively) and the members of the Group's senior management (the "**Management**") are not residents of the United States, and a substantial portion of the Company's assets are located outside the United States. As a result, it may be difficult for investors in the United States to effect service of process on the Company or its Board Members and members of Management in the United States or to enforce in the United States judgments obtained in U.S. courts against the Company or those persons, including judgments based on the civil liability provisions of the securities laws of the United States or any State or territory within the United States.

Uncertainty exists as to whether courts in Norway will enforce judgments obtained in other jurisdictions, including the United States, against the Company or its Board Members or members of Management under the securities laws of those jurisdictions or entertain actions in Norway against the Company or its Board Members or members of Management under the securities laws of other jurisdictions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may not be enforceable in Norway. The United States does not currently have a treaty providing for reciprocal recognition and enforcement of judgements (other than arbitral awards) in civil and commercial matters with Norway.

AVAILABLE INFORMATION

The Company has agreed that, for so long as any of the Offer Shares are "restricted securities" within the meaning of Rule 144(a)(3) under the U.S. Securities Act, it will, during any period in which it is neither subject to Sections 13 or 15(d) of the U.S. Securities Exchange Act of 1934, as amended (the "**U.S. Exchange Act**"), nor exempt from reporting pursuant to Rule 12g3-2(b) under the U.S. Exchange Act, provide to any holder or beneficial owners of Shares, or to any prospective purchaser designated by any such registered holder, upon the request of such holder, beneficial owner or prospective owner, the information required to be delivered pursuant to Rule 144A(d)(4) of the U.S. Securities Act. The Company is not currently subject to the periodic reporting and other information requirements of the U.S. Exchange Act.

TABLE OF CONTENTS

1	SUMMARY	3
2	RISK FACTORS	10
	2.1 Risks related to the Shares	10
	2.2 Risks related to the Rights Issue	10
3	RESPONSIBILITY FOR THE SECURITIES NOTE AND THE PROSPECTUS	12
4	GENERAL INFORMATION	13
	4.1 The approval of this Securities Note by the Norwegian Financial Supervisory Authority	13
	4.2 Prospectus	13
	4.3 Other important investor information	13
	4.4 Presentation of other information	13
5	USE OF PROCEEDS FROM THE RIGHTS ISSUE	14
6	DIVIDENDS	15
	6.1 Legal constraints on the distribution of dividends	15
	6.2 Manner of dividend payment	15
7	CAPITALIZATION AND INDEBTEDNESS	16
	7.1 Introduction	16
	7.2 Capitalization	16
	7.3 Net financial indebtedness	16
	7.4 Working capital statement	17
	7.5 Contingent and indirect indebtedness	17
8	CORPORATE INFORMATION AND CERTAIN ASPECTS OF NORWEGIAN CORPORATE LAW	18
	8.1 Company corporate information	18
	8.2 The Shares	18
	8.3 Certain aspects of Norwegian corporate law	18
9	SECURITIES TRADING IN NORWAY	22
	9.1 Introduction	22
	9.2 Market value of the Shares	22
	9.3 Trading and settlement	22
	9.4 Information, control and surveillance	23
	9.5 The VPS and transfer of shares	23
	9.6 Shareholder register – Norwegian law	24
	9.7 Foreign investment in shares listed in Norway	24
	9.8 Disclosure obligations	24
	9.9 Insider trading	24
	9.10 Mandatory offer requirement	24
	9.11 Compulsory acquisition	25
	9.12 Foreign exchange controls	26
10	TAXATION	27
	10.1 Norwegian taxation	27
11	THE TERMS OF THE RIGHTS ISSUE	32
	11.1 Overview	32
	11.2 Resolution to issue the Offer Shares	32
	11.3 Conditions for completion of the Rights Issue	34
	11.4 Timetable	34
	11.5 Subscription Price	34
	11.6 Subscription Period	34

11.7	Record Date for Existing Shareholders	34
11.8	Subscription Rights.....	35
11.9	Trading in Subscription Rights.....	35
11.10	Subscription procedures	36
11.11	Mandatory Anti-Money Laundering Procedures	36
11.12	Financial intermediaries.....	37
11.13	Allocation of the Offer Shares	38
11.14	Payment for the Offer Shares.....	38
11.15	Delivery of the Offer Shares.....	39
11.16	Listing of the Offer Shares	39
11.17	The rights conferred by the Offer Shares	40
11.18	NCI code and LEI number.....	40
11.19	VPS registration	40
11.20	Dilution	40
11.21	Timeliness, validity, form and eligibility of subscriptions	41
11.22	Share capital following the Rights issue	41
11.23	The Underwriting.....	41
11.24	Net proceeds and expenses related to the Rights Issue	42
11.25	Interest of natural and legal persons involved in the Rights Issue.....	42
11.26	Participation of major Existing Shareholders and members of the Company's Management, supervisory and administrative bodies in the Rights issue.....	42
11.27	Publication of information relating to the Rights Issue	43
11.28	Product Governance.....	43
11.29	Governing law and jurisdiction	43
11.30	Advisors in the Rights Issue.....	43
12	SELLING AND TRANSFER RESTRICTIONS.....	44
12.1	General.....	44
12.2	United States.....	46
12.3	United Kingdom	48
12.4	European Economic Area	49
12.5	Switzerland	49
12.6	Additional Jurisdictions.....	49
13	DEFINITIONS AND GLOSSARY	50

APPENDICES

APPENDIX A SUBSCRIPTION FORM FOR THE RIGHTS ISSUE

1 SUMMARY**Introduction**

<i>Warning</i>	This Summary should be read as an introduction to the registration document dated 29 November 2021 (the " Registration Document ") and this Securities Note. Any decision to invest in the Company's securities should be based on a consideration of the Registration Document and the Securities Note by the investor. An investment in the Company's shares, including the Offer Shares (the " Shares ") involves inherent risk and the investor could lose all or part of its invested capital. Where a claim relating to the information contained in the Registration Document and/or the Securities Note is brought before a court, the plaintiff investor might, under national law, have to bear the costs of translating the Registration Document and/or the Securities Note before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled the Summary including any translation thereof, but only where the Summary is misleading, inaccurate or inconsistent, when read together with the Registration Document and/or the Securities Note, or where it does not provide, when read together with the Registration Document and/or the Securities Note, key information in order to aid investors when considering whether to invest in the Company's securities.
<i>Securities</i>	The Company has one class of shares in issue. The existing Shares are, and the Offer Shares will be, registered in book-entry form with the Norwegian Central Securities Depository (Nw.: Verdipapirsentralen) (the " VPS ") and have ISIN NO 0010689326.
<i>Issuer</i>	Targovax ASA's registration number in the Norwegian Register of Business Enterprises (Nw.: <i>Foretaksregisteret</i>) is 996 162 095 and its LEI is 5967007LIEEXZXFYNS31. The Company's registered office is located at Vollsveien 19, N-1366 Lysaker, Norway, and the Company's main telephone number at that address is +47 21 39 88 10. The Group's website can be found at www.targovax.com .
<i>Offeror(s)</i>	Not applicable. The Company offers the Offer Shares.
<i>Competent authority</i>	The Financial Supervisory Authority of Norway (Nw.: <i>Finanstilsynet</i>), with registration number 840 747 972 and registered address at Revierstredet 3, N-0151 Oslo, Norway, and with telephone number +47 22 93 98 00 has reviewed and, on 29 November 2021, approved the Registration Document and the Securities Note.

Key information on the issuer**Who is the issuer?**

<i>Corporate information</i> ...	Targovax ASA is a Norwegian public limited liability company organized and existing under the laws of Norway pursuant to the Norwegian Public Limited Liability Companies Act of 13 June 1987 no. 45 (the " Norwegian Public Limited Companies Act "). The Company was incorporated in Norway on 8 October 2010, and the Company's registration number in the Norwegian Register of Business Enterprises is 996 162 095 and its LEI is 5967007LIEEXZXFYNS31.
<i>Principal activities</i>	Targovax is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax's focus is to "activate the patient's immune system to fight cancer", thus extending and transforming the lives of cancer patients with targeted cancer immunotherapies. The Group's pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient's own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile. Further, the products are well positioned for combinations with other treatment approaches, including other immunotherapies, surgery, radiation and chemotherapy. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. In many patients studied in the Group's clinical trials, on injection of ONCOS-102, the immune system is activated, leading to infiltration of immune cells into the tumor, priming of cancer-specific T-cells and a subsequent systemic anti-tumor immune response. This immune activation mediated by ONCOS-102 has been demonstrated in various solid tumor indications, both as monotherapy and in combination with checkpoint inhibitors and chemotherapy. The

Group has research programs on potential next generation oncolytic virus candidates, with the intention to advance these into clinical development based on expected pre-clinical data. The next generation oncolytic viruses are based on the ONCOS adenovirus backbone, but with double transgenes and incorporating novel RNA and protein engineering concepts to broaden the mechanism of action and enhance the overall clinical effectiveness. The Group also has a mutant RAS peptide vaccine platform, with two clinical stage products TG01 and TG02. The Group is actively working to establish academic and commercial partnerships to enable low-cost continued clinical development of these products.

Major shareholders Shareholders owning 5% or more of the Shares have an interest in the Company's share capital which is notifiable pursuant to the Norwegian Securities Trading Act. To the Company's knowledge, no shareholder, other than HealthCap V L.P. (jointly with OFCO Club V) (in total 12,405,584 Shares, approximately 14.33%), mutual funds managed by Nordea Funds (4,474,325 Shares, approximately 5.17%) and Radiumhospitalets Forskningsstiftelse (4,427,255 Shares, approximately 5.11%), held more than 5% or more of the issued Shares as at 19 November 2021.

Key managing directors. The Company's management team consists of seven individuals. The names of the members of the management and their respective positions are presented in the table below.

Name	Position
Erik Digman Wiklund.....	Chief Executive Officer
Øystein Soug	Special Advisor and interim Chief Financial Officer
Magnus Jäderberg	Chief Medical Officer
Victor Levitsky	Chief Scientific Officer
Lone Ottesen	Chief Development Officer
Ola Melin	Head of Manufacturing
Ingunn M. Lindvig.....	VP, Regulatory Affairs

Statutory auditor PricewaterhouseCoopers AS (PwC), with business registration number 987 009 713 in the Norwegian Register of Business Enterprises and registered address at Dronning Eufemias gate 71, N-0194 Oslo, Norway.

What is the key financial information regarding the issuer?

Income statement

In NOK thousands	Year ended		Nine months ended	
	31 December		30 September	
	2020	2019	2021	2020
	IFRS	IFRS	IAS 34	IAS 34
	<i>(audited)</i>	<i>(audited)</i>	<i>(unaudited)</i>	<i>(unaudited)</i>
Total revenue.....	624	2,251	-	34
Operating profit / loss (-)	-103,901	-150,273	-22,539	-22,039
Net profit / loss	-108,126	-147,529	-23,309	-22,684

Balance sheet

In NOK thousands	As of		As of	
	31 December		30 September	
	2020	2019	2021	2020
	IFRS	IFRS	IAS 34	IAS 34
	<i>(audited)</i>	<i>(audited)</i>	<i>(unaudited)</i>	<i>(unaudited)</i>
Total assets	520,740	456,907	442,588	508,437
Total equity	372,588	296,955	298,236	345,174

Cash flow statement

In NOK thousands	Year ended		Nine months ended	
	31 December		30 September	
	2020	2019	2021	2020
	IFRS	IFRS	IAS 34	IAS 34
	<i>(audited)</i>	<i>(audited)</i>	<i>(unaudited)</i>	<i>(unaudited)</i>
Net cash flow from / (used in) operating activities	-110,793	-142,517	-16,357	-23,252
Net cash received from / (paid in) investing activities	-70	-134	-	-

Net cash generated from / (paid in) financing activities	163,534	62,156	-551	-1,061
---	---------	--------	------	--------

What are the key risks that are specific to the issuer?

- Material risk factors*
- Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, obtain regulatory approval and become commercially viable.
 - Before the Group may obtain regulatory approvals for the commercial sale of the Group's product candidates, the Group must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that its product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.
 - The Group does not have any products that have obtained regulatory approval. Its business and future success depend on its ability to obtain regulatory approval of, and then successfully commercialize, its lead product candidate, ONCOS-102.
 - The Group depends on collaboration with partners, medical institutions and laboratories to conduct clinical testing in compliance requirements from appropriate regulatory authority in the country of use. Any significant delay or failure in the conduct of clinical studies may adversely impact the Group's ability to obtain regulatory approval for and commercialize its current and future product candidates.
 - The carrying amount of the patented technology (ONCOS-102) reflects the value of the consideration shares issued by the Company in its acquisition of Targovax Oy in 2015. The carrying amount of the patented technology constitutes a significant portion of the total assets in the Group's consolidated financial statements.
 - Undesirable side effects caused by the Group's product candidates could cause the Group or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the U.S. Food and Drug Administration (the "FDA"), the European Medicines Agency (the "EMA") or comparable foreign regulatory authorities.
 - The Group has obtained orphan drug designation in the U.S. and Europe for ONCOS-102 in malignant plural mesothelioma and ovarian cancer, but the Group may be unable to maintain the benefits associated with orphan drug designation.
 - The Group cannot be certain that it will be able to enter into or maintain satisfactory agreements with third-party suppliers.
 - Failure in the production or supply of ONCOS-102 to appropriate quality standards as set from time to time by regulatory authorities, could significantly impair the Group's ability to develop and commercialize its lead product candidate ONCOS-102.
 - The Group may be unable to enter into partnership agreements in accordance with the Group's strategy.

Key information on the securities

What are the main features of the securities?

- Type, class and ISIN* All of the Shares are common shares in the Company and have been created under the Norwegian Public Limited Companies Act. The existing Shares are, and the Offer Shares will be, registered in book-entry form with the VPS and have ISIN NO 0010689326.
- Currency, par value and number of securities* The Shares are traded in NOK on the Oslo Stock Exchange. As at the date of this Summary, the Company's share capital is NOK 8,658,240.50 divided into 86,582,405 Shares, each with a par value of NOK 0.10.
- Rights attached to the securities.....* The Company has one class of shares in issue, and in accordance with the Norwegian Public Limited Companies Act, all Shares in that class provide equal rights in the Company. Each of the Shares carries one vote.
- Transfer restrictions.....* The Shares are freely transferable. The Company's articles of association do not provide for any restrictions on the transfer of Shares or a right of first refusal for the Shares. Share transfers are not subject to approval by the Company's board of directors.

Dividend and dividend policy..... The Company has not paid any dividends for the year ended 31 December 2020 or previous years. The Group is focusing on the development of pharmaceutical products and does not anticipate paying any cash dividend until sustainable profitability is achieved.

Where will the securities be traded?

The Shares are, and the Offer Shares will be, admitted to trading on the Oslo Stock Exchange.

What are the key risks that are specific to the securities?

Material risk factors

- The Group is highly dependent on its lead candidate, ONCOS-102, to be successful. Information regarding the outcome of the Group's ongoing and future clinical trials may make the value of the Shares to fluctuate significantly.
- The Company has one major shareholder, HealthCap V L.P. ("**HealthCap**"), and its interest may conflict with those of the Company's shareholders.
- Issuance of new Shares in accordance with the Company's option program and RSU plan, or through offerings of securities in the future in order to fund the Company's operations, will cause the existing shareholders, who are not in a position to purchase additional equity securities, to be diluted.
- The trading price for the Shares has fluctuated significantly in the past. During the last two years and prior to the Company's announcement of the Rights Issue on 4 November 2021, the trading price of the Shares on the Oslo Stock Exchange has varied between a low of NOK 2.65 immediately following the COVID-19 outbreak, and a high of NOK 7.8 in December 2020. Thus, the Shares have during the last two years traded above the Subscription Price of NOK 1.72. As such, there has been significant fluctuations in the trading volume for the Shares during a short period of time. The Offer Shares will not be delivered to the investors immediately following subscription, meaning that there is a risk that the Shares in the period from the investor's subscription of Offer Shares until delivery of the Offer Shares may trade below the Subscription Price due to, inter alia, the current volatility in the Norwegian and global equity capital markets. If the Shares trade below the Subscription Price, this will result in a loss of investment in the Offer Shares for the investor irrevocably committing to subscribe for the Offer Shares.

Key information on the offer of securities to the public and/or the admission to trading on a regulated market

Under which conditions and timetable can I invest in this security?

Terms and conditions of the offering..... The Rights Issue consists of an offer by the Company of 101,744,186 Offer Shares, each with a par value of NOK 0.10, at a Subscription Price of NOK 1.72 per Offer Share, thereby raising gross proceeds of approximately NOK 175 million.

Existing Shareholders will be granted tradable Subscription Rights that, subject to applicable law, provide a preferential right to subscribe for, and be allocated, Offer Shares at the Subscription Price in the Rights Issue. Over-subscription and subscription without Subscription Rights are permitted but there can be no assurance that Offer Shares will be allocated for such subscriptions.

The Subscription Price in the Rights Issue is NOK 1.72 per Offer Share.

The Subscription Period will commence at 09:00 hours (CET) on 30 November 2021 and end at 16:30 hours (CET) on 14 December 2021. The Subscription Period may not be shortened, but the Board of Directors may extend the Subscription Period if this is required by law due to the publication of a supplement to the Prospectus.

The Subscription Rights will be credited to and registered on each Existing Shareholder's VPS account on or about 30 November 2021 under ISIN NO 0011147696. The Subscription Rights will be distributed free of charge to Existing Shareholders.

The Subscription Rights, including acquired Subscription Rights, must be used to subscribe for Offer Shares before the end of the Subscription Period (i.e. 14 December 2021 at 16:30 hours (CET)) or sold before 10 December 2021 at 16:30 hours (CET). Subscription Rights that are not sold before 10 December 2021 at 16:30 hours (CET) or exercised before 14 December 2021 at 16:30 hours (CET) will have no value and will

lapse without compensation to the holder. Holders of Subscription Rights (whether granted or acquired) should note that subscriptions for Offer Shares must be made in accordance with the procedures set out in this Securities Note and that the acquisition of Subscription Rights does not in itself constitute a subscription for Offer Shares.

Timetable in the offering.. The key dates in the Rights Issue are set out below.

Last day of trading in the Shares including Subscription Rights	25 November 2021
First day of trading in the Shares excluding Subscription Rights	26 November 2021
Record Date	29 November 2021
Subscription Period commences	30 November 2021 at 09:00 hours (CET)
Trading in Subscription Rights commences on the Oslo Stock Exchange.....	30 November 2021 at 09:00 hours (CET)
Trading in Subscription Rights ends.....	10 December 2021 at 16:30 hours (CET)
Subscription Period ends.....	14 December 2021 at 16:30 hours (CET)
Allocation of the Offer Shares	Expected on or about 15 December 2021
Distribution of allocation letters	Expected on or about 15 December 2021
Payment Date.....	Expected on or about 17 December 2021
Registration of the share capital increase with the Norwegian Register of Business Enterprises .	Expected on or about 21 December 2021
Delivery of the Offer Shares	Expected on or about 22 December 2021
Listing and commencement of trading in the Offer Shares on the Oslo Stock Exchange.....	Expected on or about 22 December 2021

Admission to trading The Shares are listed on the Oslo Stock Exchange under ISIN NO 0010689326 and ticker code "TRVX". The Offer Shares will be listed on the Oslo Stock Exchange as soon as the share capital increase pertaining to the Rights Issue has been registered with the Norwegian Register of Business Enterprises and the Offer Shares have been registered in the VPS. The listing is expected to take place on or about 22 December 2021.

Distribution plan..... Allocation of the Offer Shares will take place on or about 15 December 2021 in accordance with the following criteria:

- (i) Allocation of Offer Shares to subscribers will be made in accordance with granted and acquired Subscription Rights which have been validly exercised during the Subscription Period. Each Subscription Right will give the right to subscribe for and be allocated one Offer Share in the Rights Issue.
- (ii) Any unallocated Offer Shares following the allocation under item (i) above shall be allocated to those Underwriters who have subscribed Offer Shares in the Subscription Period, limited upwards to their respective underwriting obligation.
- (iii) If not all Subscription Rights are validly exercised during the Subscription Period and there are remaining unallocated Offer Shares following the allocation to the Underwriters who have subscribed Offer Shares in the Subscription Period pursuant to items (i) and (ii) above, subscribers who have exercised their Subscription Rights and who have over-subscribed, will be allocated additional Offer Shares on a pro rata basis based on the number of Subscription Rights exercised by each such subscriber. To the extent that pro rata allocation is not possible, the Company will determine the allocation by the drawing of lots.
- (iv) Offer Shares not allocated pursuant to item (i) to (iii) above, will be allocated to subscribers not holding Subscription Rights. Allocation will be sought made on a pro rata basis based on their respective subscription amounts.
- (v) Any Offer Shares remaining after allocation pursuant to (i) and (iv) above, will be subscribed by, and allocated to, the Underwriters pursuant to, and in accordance with, the underwriting obligation of the respective Underwriters.

No fractional Offer Shares will be allocated. The Company reserves the right to round off, reject or reduce any subscription for Offer Shares not covered by Subscription Rights (i.e. over-subscription or subscriptions made without Subscription Rights) and will only allocate such Offer Shares to the extent that Offer Shares are available to cover over-

subscription based on Subscription Rights or subscriptions made without Subscription Rights. Allocation of fewer Offer Shares than subscribed for by a subscriber will not impact on the subscriber's obligation to pay for the number of Offer Shares allocated.

Any Offer Shares that are unsubscribed by the end of the Subscription Period, will be subscribed by the Underwriters in accordance with their underwriting obligations.

Dilution The following table shows a comparison of participation in the Company's share capital and voting rights for existing shareholders before and after the Rights Issue, with the assumption that existing shareholders do not subscribe for Offer Shares and assuming that all the Offer Shares are issued:

	<u>Prior to the Rights Issue</u>	<u>Subsequent to the Rights Issue</u>
Total number of Shares each with a par value of NOK 0.10	86,582,405	188,326,591
% dilution		54%

Total expenses of the issue/offer The total costs and expenses related to the Rights Issue are estimated to amount to approximately NOK 25 million. No expenses or taxes will be charged by the Company or the Managers to the applicants in the Rights Issue.

Who is the offeror and/or the person asking for admission to trading?

Brief description of the offeror(s) Not applicable. The Company offers the Offer Shares.

Why are the Registration Document and the Securities Note being produced?

Reasons for the offer/admission to trading The expected net proceeds from the Rights Issue are expected to finance the Group into Q3 of 2023.

Use of proceeds The Company anticipates that it will use existing cash and net proceeds from the Rights Issue as follows:

- Colorectal cancer: Read out of collaboration trial in colorectal cancer with peritoneal disease, ~30 patients 1H 2022;
- Mesothelioma: Phase I/II combination trial with SoC chemo, 30 months mOS data Q4 2021;
- Melanoma: Start the PD-1 refractory melanoma Phase II platform trial to explore multiple ONCOS-102 combinations, first patient expected in 2H 2022;
- Manufacturing of clinical material for trials during the period;
- Continue selective development activities for large scale manufacturing of ONCOS-102;
- Data from in-vitro study with circular RNA, in the development of a novel platform system for gene delivery and next generation RNA concepts with ONCOS delivery vector;
- In vivo proof of concept data of ONCOS-102 systemic IV delivery;
- Bring next generation TG to the clinic with academic and commercial collaborators;
- Explore novel MutRAS projects;
- Maintain and build the patent portfolio; and
- General corporate purposes.

Underwriting The Company and the Underwriters have entered into the Underwriting Agreement dated 3 November 2021, pursuant to which the Underwriters have undertaken, severally and not jointly, to underwrite an aggregate amount of NOK 166,915,000 in the Rights Issue. The Underwriters have, limited to their respective underwritten amounts, undertaken to subscribe and pay for the Offer Shares not subscribed for during the Subscription Period on or prior to the payment date in the Rights Issue. In addition, AP4 (The Fourth Swedish National Pension Fund) has indicated a pro rata subscription in the Rights Issue, bringing the total underwritten and pre-subscribed amount to approximately NOK 175,000,000.

Conflicts of interest The Managers or their respective affiliates have provided from time to time, and may provide in the future, investment and commercial banking services to the Company and

its affiliates in the ordinary course of business, for which they may have received and may continue to receive customary fees and commissions. The Managers, their respective employees and any affiliates may currently own existing Shares in the Company. Further, in connection with the Rights Issue, the Managers, their respective employees and any affiliates acting as an investor for its own account may receive Subscription Rights (if they are Existing Shareholders) and may exercise its right to take up such Subscription Rights and acquire Offer Shares, and, in that capacity, may retain, purchase or sell Subscription Rights or Offer Shares and any other securities of the Company or other investments for its own account and may offer or sell such securities (or other investments) otherwise than in connection with the Rights Issue. The Managers do not intend to disclose the extent of any such investments or transactions otherwise than in accordance with any legal or regulatory obligation to do so. Further, the Managers and the Underwriters will receive fees in connection with the Rights Issue, and, as such, have an interest in the Rights Issue.

Beyond the abovementioned, the Company is not aware of any interest, including conflicting ones, of natural and legal persons involved in the Rights Issue.

2 RISK FACTORS

*An investment in the Company and the Shares involves inherent risk. Before making an investment decision with respect to the Shares, investors should carefully consider the risk factors and all information contained in this Securities Note and the Prospectus (as defined in Section 4.2 "Prospectus", including the Company's financial information incorporated by reference into the Registration Document (the "**Financial Information**"), and the related notes to such Financial Information. The risks and uncertainties described in this Section 2 "Risk Factors" are the material known risks and uncertainties specific for the Shares as of the date hereof that the Company believes are the material risks relevant to an investment in the Shares. An investment in the Shares is suitable only for investors who understand the risks associated with this type of investment and who can afford to lose all or part of their investment.*

The risk factors included in this Section 2 "Risk Factors" are presented in a limited number of categories, where each risk factor is sought placed in the most appropriate category based on the nature of the risk it represents. Within each category the risk factors deemed most material for the Group, taking into account their potential negative affect and the probability of their occurrence, are set out first. This does not mean that the remaining risk factors are ranked in order of their materiality or comprehensibility, nor based on a probability of their occurrence. The absence of negative past experience associated with a given risk factor does not mean that the risks and uncertainties in that risk factor are not genuine and potential threats, and they should therefore be considered prior to making an investment decision. If any of the following risks were to materialize, either individually, cumulatively or together with other circumstances, it could have a material adverse effect on the Group and/or its business, results of operations, cash flows, financial condition and/or prospects, which may cause a decline in the value and trading price of the Shares, resulting in loss of all or part of an investment in the Shares.

2.1 Risks related to the Shares

The Company has one major shareholder and its interest may conflict with those of the Company's shareholders

As at the date of this Securities Note, HealthCap V L.P. ("**HealthCap**") controls approximately 14% of the Shares and is represented at the Board of Directors with two Board Members and will, as the major shareholder of the Company, have the ability to significantly influence the outcome of matters submitted for the vote by the Company's shareholders, including election of members of the Board of Directors. The commercial goals of HealthCap as shareholder, and those of the Company, may not always remain aligned and this concentration of ownership may not always be in the best interest of the Company's other shareholders.

The market value of the Shares may fluctuate significantly, which could cause investors to lose a significant part of their investment

The Group is highly dependent on its lead candidate, ONCOS-102, to be successful. Information regarding the outcome of the Group's ongoing and future clinical trials may cause the value of the Shares to fluctuate significantly, which could cause investors to lose a significant part of their investment. In the next 12 months' period from the date hereof, the Company will have several readouts from its ONCOS-102 clinical trials. The outcome and public disclosure of the results from these clinical readouts are expected to have a direct influence on the trading price of the Shares. Further, the market value of the Shares as expressed in foreign currencies will fluctuate in part as a result of foreign exchange fluctuations. This could affect the value of the Shares and of any dividends paid on the Shares for an investor whose principal currency is not NOK.

The Group has a share option program for its employees and a restricted stock units ("RSUs") plan for the members of the Board of Directors, entitling the holder of such securities to receive Shares

The Company has issued share options under its share option program and RSUs under its plan for restricted stock units, and expects to issue additional securities under both the share option program and RSU plan. When the underlying options and RSUs are exercised/settled, the Company is obligated to honor these by issuance of new Shares to the holder or by cash settlements if the Company does not have the ability to settle these with Shares. The Group also expects to conduct further offerings of securities in the future in order to fund its operations. By issuing new Shares, existing shareholders who are not in a position to purchase additional equity securities will be diluted.

2.2 Risks related to the Rights Issue

Existing Shareholders who do not participate in the Rights Issue may experience a significant dilution of their shareholding

Subscription Rights that are not sold before 16:30 CET on 10 December 2021 or exercised by the end of the Subscription Period will have no value and will automatically lapse without compensation to the holder. To the extent that an Existing

Shareholder does not sell its Subscription Rights before 16:30 CET on 10 December 2021 or exercises its Subscription Rights prior to the expiry of the Subscription Period, whether by choice or due to a failure to comply with the procedures set forth in Section 11 "The terms of the Rights Issue", or to the extent that an Existing Shareholder is not permitted to subscribe for Offer Shares as further described in Section 12 "Selling and Transfer Restrictions", such Existing Shareholder's proportionate ownership and voting interests in the Company after the completion of the Rights Issue will be diluted. Even if an Existing Shareholder chooses to sell its unexercised Subscription Rights, or such Subscription Rights are sold on its behalf, the consideration it receives in the trading market for the Subscription Rights may not reflect the immediate dilution in its shareholding resulting from the completion of the Rights Issue.

The Shares have traded above the Subscription Price during the last two years, and there cannot be any guarantees that participation in the Rights Issue will not result in loss of investment

A subscription of Offer Shares in the Rights Issue is binding and irrevocable, and cannot be withdrawn, cancelled or modified by the subscriber after having been received by the Managers, or in the case of subscriptions through the VPS online subscription system, upon registration of the subscription. The trading price for the Shares has fluctuated significantly in the past. During the last two years and prior to the Company's announcement of the Rights Issue on 4 November 2021, the trading price of the Shares on the Oslo Stock Exchange has varied between a low of NOK 2.65 immediately following the COVID-19 outbreak, and a high of NOK 7.8 in December 2020. Thus, the Shares have during the last two years traded above the Subscription Price of NOK 1.72. As such, there has been significant fluctuations in the trading volume for the Shares during a short period of time. The Subscription Price in the Share Issue is below the last reported trading price prior to the date of this Securities Note. The Offer Shares will not be delivered to the investors immediately following subscription, meaning that there is a risk that the Shares in the period from the investor's subscription of Offer Shares until delivery of the Offer Shares may trade below the Subscription Price due to, *inter alia*, the current volatility in the Norwegian and global equity capital markets. If the Shares trade below the Subscription Price, this will result in a loss of investment in the Offer Shares for the investor irrevocably committing to subscribe for the Offer Shares.

3 RESPONSIBILITY FOR THE SECURITIES NOTE AND THE PROSPECTUS

The Prospectus (as defined in Section 4.2 "Prospectus" below), including this Securities Note, has been prepared in connection with the Rights Issue and the listing of the Offer Shares on the Oslo Stock Exchange.

The Board of Directors of Targovax ASA accepts responsibility for the information contained in the Prospectus, including this Securities Note. The members of the Board of Directors confirm that, to the best of their knowledge, the information contained in the Prospectus, including the Securities Note, is in accordance with the facts and contains no omission likely to affect its import.

29 November 2021

The Board of Directors of Targovax ASA

Damian Marron
Chairperson

Bente-Lill Bjerkelund Romøren
Board member

Sonia Quaratino
Board member

Per Samuelsson
Board member

Robert Burns
Board member

Johan Christenson
Board member

Eva-Lotta Allan
Board member

Diane Mellett
Board member

4 GENERAL INFORMATION

4.1 The approval of this Securities Note by the Norwegian Financial Supervisory Authority

The Financial Supervisory Authority of Norway (Nw.: *Finanstilsynet*) (Norwegian FSA) has reviewed and approved this Securities Note, as competent authority under Regulation (EU) 2017/1129 (EU Prospectus Regulation). The Norwegian FSA only approves this Securities Note as meeting the standards of completeness, comprehensibility and consistency imposed by the EU Prospectus Regulation, and such approval should not be considered as an endorsement of the issuer or the quality of the securities that are the subject of this Securities Note. This Securities Note was approved by the Norwegian FSA on 29 November 2021. The Securities Note has been drawn up as part of a simplified prospectus in accordance with Article 14 of Regulation (EU) 2017/1129 (the EU Prospectus Regulation). Investors should make their own assessment as to the suitability of investing in the securities.

4.2 Prospectus

In connection with the Rights Issue and the listing of the Offer Shares on the Oslo Stock Exchange, the Company has prepared a prospectus, comprising this Securities Note and the Registration Document dated 29 November 2021 as approved by the Norwegian FSA on 29 November 2021 (jointly, the "**Prospectus**").

4.3 Other important investor information

The Company has furnished the information in this Securities Note. No representation or warranty, express or implied is made by the Managers as to the accuracy, completeness or verification of the information set forth herein, and nothing contained in this Securities Note is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or the future. The Managers assume no responsibility for the accuracy or completeness or the verification of this Securities Note and accordingly disclaim, to the fullest extent permitted by applicable law, any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this Securities Note or any such statement.

Neither the Company nor the Managers, or any of their respective affiliates representatives, advisers or selling agents, is making any representation to any offeree or purchaser of the Offer Shares or holder of the Subscription Rights regarding the legality of an investment in the Offer Shares or the Subscription Rights. Each investor should consult with his or her own advisors as to the legal, tax, business, financial and related aspects of a purchase of the Offer Shares and the use of the Subscription Rights to subscribe for Offer Shares.

Each investor should make its own assessment as to the suitability of investing in the Shares and should consult with his or her own advisors as to the legal, tax, business, financial and related aspects of an investment in the Shares.

Investing in the Shares involves a high degree of risk. See Section 2 "Risk Factors" beginning on page 10 herein and Section 1 "Risk Factors" of the Registration Document beginning on page 3 therein.

4.4 Presentation of other information

4.4.1 Industry and market data

The Company has furnished the information in this Securities Note and the Securities Note does not contain information that has been sourced from third parties.

4.4.2 Other information

In this Securities Note, all references to "**NOK**" are to the lawful currency of Norway, all references to "**EUR**" are to the lawful common currency of the EU member states who have adopted the Euro as their sole national currency, all references to "**USD**" or "**U.S. Dollar**" are to the lawful currency of the United States. No representation is made that the NOK, EUR or USD amounts referred to herein could have been or could be converted into NOK, EUR or USD, as the case may be, at any particular rate, or at all. The Financial Information is published in NOK.

4.4.3 Rounding

Certain figures included in this Securities Note have been subject to rounding adjustments (by rounding to the nearest whole number or decimal or fraction, as the case may be). Accordingly, figures shown for the same category presented in different tables may vary slightly. As a result of rounding adjustments, the figures presented may not add up to the total amount presented.

5 USE OF PROCEEDS FROM THE RIGHTS ISSUE

The expected net proceeds from the Rights Issue are expected to finance the Group into Q3 of 2023.

The Company currently anticipates that it will use existing cash and net proceeds from the Rights Issue for the following activities and purposes:

- Colorectal cancer: Read out of collaboration trial in colorectal cancer with peritoneal disease, ~30 patients 1H 2022;
- Mesothelioma: phase 1/2 combination trial with SoC chemo, 30 months mOS data Q4 2021;
- Melanoma: Start the PD-1 refractory melanoma phase 2 platform trial to explore multiple ONCOS-102 combinations, first patient expected in 2H 2022;
- Manufacturing of clinical material for trials during the period;
- Continue selective development activities for large scale manufacturing of ONCOS-102;
- Data from in-vitro study with circular RNA, in the development of a novel platform system for gene delivery and next generation RNA concepts with ONCOS delivery vector;
- In vivo proof of concept data of ONCOS-102 systemic IV delivery;
- Bring next generation TG to the clinic with academic and commercial collaborators;
- Explore novel MutRAS projects;
- Maintain and build the patent portfolio; and
- General corporate purposes.

At the date of the Securities Note, the Company cannot predict all the specific uses for the net proceeds, or the actual amounts that will be spent on the uses described above. The exact amounts and the timing of the actual use of the net proceeds will depend on numerous factors, among others, progress, costs and results of the Group's preclinical and clinical development program, as well as other developments in the field of cancer treatment, including changes in the regulatory environment.

6 DIVIDENDS

6.1 Legal constraints on the distribution of dividends

In deciding whether to propose a dividend and in determining the dividend amount in the future, the Board of Directors must take into account applicable legal restrictions, as set out in the Norwegian Public Limited Companies Act of 13 June 1997 no. 45 (the "**Norwegian Public Limited Companies Act**"), the Company's capital requirements, including capital expenditure requirements, its financial condition, general business conditions and any restrictions that its contractual arrangements in place at the time of the dividend may place on its ability to pay dividends and the maintenance of appropriate financial flexibility. Except in certain specific and limited circumstances set out in the Norwegian Public Limited Companies Act, the amount of dividends paid may not exceed the amount recommended by the Board of Directors.

Dividends may be paid in cash, or in some instances, in kind. The Norwegian Public Limited Companies Act provides the following constraints on the distribution of dividends applicable to the Company:

- Section 8-1 of the Norwegian Public Limited Companies Act regulates what may be distributed as dividend, and provides that the Company may distribute dividends only to the extent that the Company after said distribution still has net assets to cover (i) the share capital and (ii) other restricted equity (i.e. the reserve for unrealized gains and the reserve for valuation of differences).

The calculation of the distributable equity shall be made on the basis of the balance sheet included in the approved annual accounts for the last financial year, provided, however, that the registered share capital as of the date of the resolution to distribute dividend shall be applied. Following the approval of the annual accounts for the last financial year, the general meeting of the Company ("**General Meeting**") may also authorize the Board of Directors to declare dividends on the basis of the Company's audited annual accounts. Dividends may also be resolved by the General Meeting based on an interim balance sheet which has been prepared and audited in accordance with the provisions applying to the annual accounts and with a balance sheet date not further into the past than six months before the date of the General Meeting's resolution.

- Dividends can only be distributed to the extent that the Company's equity and liquidity following the distribution is considered sound.

Pursuant to the Norwegian Public Limited Companies Act, the time when an entitlement to dividend arises depends on what was resolved by the general meeting when it resolved to issue new shares in the company. A subscriber of new shares in a Norwegian public limited company will normally be entitled to dividends from the time when the relevant share capital increase is registered with the Norwegian Register of Business Enterprises. The Norwegian Public Limited Companies Act does not provide for any time limit after which entitlement to dividends lapses. Subject to various exceptions, Norwegian law provides a limitation period of three years from the date on which an obligation is due. There are no dividend restrictions or specific procedures for non-Norwegian resident shareholders to claim dividends.

In addition, U.S. federal securities laws may restrict the Company's ability to offer distributions in kind in the form of securities to certain shareholders.

6.2 Manner of dividend payment

The Company's equity capital is denominated in Norwegian kroner and all dividends on the Shares will therefore be declared in Norwegian kroner. As such, investors whose reference currency is a currency other than the Norwegian krone may be affected by currency fluctuations in the value of the Norwegian krone relative to such investor's reference currency in connection with a dividend distribution by the Company. Any future payments of dividends on the Shares to shareholders will be denominated in the currency of the bank account of the relevant shareholder, and will be paid to the shareholders through VPS. Shareholders registered in the VPS who have not supplied the VPS with details of their bank account, will not receive payment of dividends unless they register their bank account details with the VPS registrar (Nordea Bank Norge ASA ("**Nordea**")). The exchange rate(s) that is applied when denominating any future payments of dividends to the relevant shareholder's currency will be Nordea's exchange rate on the payment date. Dividends will be credited automatically to the VPS registered shareholders' accounts, or in lieu of such registered account, at the time when the shareholder has provided Nordea with its bank account details, without the need for shareholders to present documentation proving their ownership of the Shares. The shareholders' right to payment of dividends will lapse three years following the resolved payment date for those shareholders who have not registered their bank account details with Nordea within such date. Following the expiry of such date, the remaining, not distributed dividend will be returned from Nordea to the Company.

7 CAPITALIZATION AND INDEBTEDNESS

The information presented below should be read in conjunction with the Financial Information.

7.1 Introduction

This Section provides information about the Group's unaudited capitalization and net financial indebtedness on an actual basis as at 30 September 2021 and, in the "As adjusted" column, the Group's unaudited capitalization and net financial indebtedness on an adjusted basis to give effect to the material post-balance sheet events and effects of (i) that the Group's cash balance has been reduced with approximately NOK 16 million in the period from 30 September 2021 to the date of this Securities Note, and (ii) the Rights Issue to be completed in December 2021, as described in Section 11 "The terms of the Rights Issue", raising gross proceeds of approximately NOK 175 million, of which approximately NOK 25 million will be used to cover expected and estimated costs, fees, underwriting commission and expenses pertaining to the Rights Issue. Other than this, there has been no material change to the Group's capitalization and net financial indebtedness since 30 September 2021.

7.2 Capitalization

<i>In NOK thousand</i>	As of 30 September 2021 (unaudited)	Adjustment for reduced cash balance (unaudited)	Adjustment for the Rights Issue (unaudited)	As adjusted (unaudited)
Total current debt	27,004	-	-	27,004
Guaranteed ^{1, 2}	2,061	-	-	2,061
Secured	-	-	-	-
Unguaranteed/unsecured	24,943	-	-	24,943
Total non-current debt	117,349	-	-	117,349
Guaranteed ²	55,308	-	-	55,308
Secured	-	-	-	-
Unguaranteed/unsecured ³	62,041	-	-	62,041
Shareholders' equity	298,236	-16,064	150,000	432,172
Share capital	8,658	-	10,174	18,833
Legal reserves	1,046,545	-	139,826	1,186,370
Other reserves ⁴	-756,967	-16,064	-	-773,031
Total	442,588	-16,064	150,000	576,524

1 NOK 2,061 thousand of the loan from Business Finland was short-term as of 30 September 2021.

2 The Company has issued an on-demand guarantee in favour of Business Finland for the repayment obligation of Targovax Oy related to this debt.

3 Contains deferred tax (NOK 60,371 thousand) and lease liabilities (NOK 1,670 thousand).

4 Contains other reserves (NOK 58,019 thousand), retained earnings (NOK -849,466 thousand) and translation differences (NOK 34,479 thousand).

7.3 Net financial indebtedness

<i>In NOK thousand</i>	As of 30 September 2021 (unaudited)	Adjustment for reduced cash balance (unaudited)	Adjustment for the Rights Issue (unaudited)	As adjusted (unaudited)
<i>Net indebtedness</i>				
(A) Cash	36,760	-4,080	150,000	182,680
(B) Cash equivalents	17,304	-11,984	-	5,320
(C) Other current financial assets	7,320	-	-	7,320
(D) Liquidity (A + B + C)	61,384	-16,064	150,000	195,320
(E) Current financial debt	23,659	-	-	23,659
(F) Current portion of non- current debt	3,345	-	-	3,345
(G) Current financial indebtedness (E + F)	27,004	-	-	27,004

<i>In NOK thousand</i>	As of 30 September 2021 (unaudited)	Adjustment for reduced cash balance (unaudited)	Adjustment for the Rights Issue (unaudited)	As adjusted (unaudited)
(H) Net current financial indebtedness (G - D)	-34,380	16,064	-150,000	-168,316
(I) Non-current financial debt	55,308	-	-	55,308
(J) Debt instruments	-	-	-	-
(K) Non-current trade and other payables	1,670	-	-	1,670
(L) Non-current financial indebtedness (I + J + K)¹	56,978	-	-	56,978
(M) Total financial indebtedness (H + L)	22,598	16,064	-150,000	-111,338

¹ Non-current financial indebtedness does not include deferred tax (NOK 60,371 thousand) as of 30 September 2021.

7.4 Working capital statement

The Company is of the opinion that the working capital available to the Group is insufficient for the Group's present requirements, for the period covering at least 12 months from the date of this Securities Note. Unless additional capital is raised through the Rights Issue (see Section 11 "The terms of the Rights Issue"), the Company expects that it may not be able to satisfy its liabilities as they fall due during first quarter of 2022.

According to the Group's current proposed scale of operations, the Group expects that it will need approximately NOK 85 million in order to have sufficient working capital for the period covering at least 12 months from the date of the Securities Note. The Group expects to obtain the required working capital through the Rights Issue. As the entire gross proceeds in the Rights Issue is fully underwritten through a combination of i) pro rata subscriptions by the existing shareholder AP4 (The Fourth Swedish National Pension Fund), and ii) by the Underwriters, the Group believes that the Rights Issue raising gross proceeds of approximately NOK 175 million will be completed.

7.5 Contingent and indirect indebtedness

As at 30 September 2021 and as at the date of the Securities Note, the Group did not have any contingent or indirect indebtedness.

8 CORPORATE INFORMATION AND CERTAIN ASPECTS OF NORWEGIAN CORPORATE LAW

8.1 Company corporate information

The Company's legal and commercial name is Targovax ASA. The Company is a public limited company organized and existing under the laws of Norway pursuant to the Norwegian Public Limited Companies Act. The Company was incorporated in Norway on 8 October 2010 and was converted into a public limited company on 29 September 2015. The Company's registration number in the Norwegian Register of Business Enterprises is 996 162 095. The Company's legal entity identifier ("LEI") is 5967007LIEEXZXFYNS31.

The Shares are freely transferable. The Shares are registered in book-entry form with the VPS under ISIN NO 0010689326. The Company's register of shareholders in the VPS is administrated by Nordea Bank Norge ASA, Securities Services – Issuer Services, Middelthuns gate 17, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway (Nordea).

The Company's registered office is located at Vollsveien 19, N-1366 Lysaker, Norway and the Company's main telephone number at that address is +47 21 39 88 10. The Company's website can be found at www.targovax.com. The content of www.targovax.com is not incorporated by reference into and does not otherwise form part of this Securities Note.

8.2 The Shares

8.2.1 Listing on the Oslo Stock Exchange

The Shares are, and the Offer Shares will be, admitted to trading on the Oslo Stock Exchange. The Company has not applied for admission to trading of the Shares on any other stock exchange or regulated market.

8.2.2 Authorization to increase the share capital and to issue Shares

At the annual General Meeting held on 17 March 2021, the Board of Directors was granted an authorization to increase the share capital of the Company with 40% of the share capital, i.e. by up to up to NOK 3,461,251.72, to be used to give the Board of Directors financial flexibility in connection with any acquisitions or similar transactions, or to strengthen the Company's financial position in general.

At the same annual General Meeting, the Board of Directors was granted an authorization to increase the share capital by 10% of the Company's share capital, i.e. by up to NOK 865,313 to be used in connection with (i) the share based incentive programs for the Group's employees and (ii) the RSU program for the Board of Directors.

The aforementioned authorizations are valid until the annual General Meeting in 2022, but no longer than until 30 June 2022.

The preferential rights of the existing shareholders to subscribe for the new Shares pursuant to section 10-4 of the Norwegian Public Limited Companies Act may be deviated from with respect to the mentioned existing authorizations. The authorizations permit share capital increases against contribution in kind, but only the first-mentioned authorization permits share capital increases in connection with mergers.

8.2.3 Change of control and takeover bids

The Company's Articles of Association do not contain any provisions that would have the effect of delaying, deferring or preventing a change of control of the Company. The Shares have not been subject to any public takeover bids during the last financial year nor during the current financial year as at the date of this Securities Note.

8.2.4 Shareholder rights

The Company has one class of shares in issue, and in accordance with the Norwegian Public Limited Companies Act, all Shares in that class provide equal rights in the Company, including the right to any dividends. Each of the Shares carries one vote.

8.3 Certain aspects of Norwegian corporate law

8.3.1 General meetings

Through the general meeting, shareholders exercise supreme authority in a Norwegian company. In accordance with Norwegian law, the annual general meeting of shareholders is required to be held each year on or prior to 30 June. Norwegian law requires that written notice of annual general meetings setting forth the time of, the venue for and the agenda of the meeting be sent to all shareholders with a known address no later than 21 days before the annual general meeting of a Norwegian public limited company listed on a stock exchange or a regulated market shall be held, unless

the articles of association stipulate a longer deadline, which is not currently the case for the Company.

A shareholder may vote at the general meeting either in person or by proxy appointed at their own discretion. Although Norwegian law does not require the Company to send proxy forms to its shareholders for General Meetings, the Company plans to include a proxy form with notices of General Meetings. All of the Company's shareholders who are registered in the register of shareholders maintained with the VPS as of the date of the General Meeting, or who have otherwise reported and documented ownership to Shares, are entitled to participate and vote at General Meetings, however so that Shares that are registered by a nominee in the VPS register must be reregistered in a separate VPS account in the name of the beneficial shareholder prior to the General Meeting in order for the beneficial shareholder to be able to participate and vote for his/her Shares.

Apart from the annual general meeting, extraordinary general meetings of shareholders may be held if the board of directors considers it necessary. An extraordinary general meeting of shareholders must also be convened if, in order to discuss a specified matter, the auditor or shareholders representing at least 5% of the share capital demands this in writing. The requirements for notice and admission to the annual general meeting also apply to extraordinary general meetings. However, the annual general meeting of a Norwegian public limited company may with a majority of at least two-thirds of the aggregate number of votes cast as well as at least two-thirds of the share capital represented at a general meeting resolve that extraordinary general meetings may be convened with a 14 day notice period until the next annual general meeting provided the Company has procedures in place allowing shareholders to vote electronically.

8.3.2 Voting rights – Amendments of the Articles of Association

Each of the Shares carries one vote. In general, decisions that shareholders are entitled to make under Norwegian law or the Articles of Association may be made by a simple majority of the votes cast. In the case of elections or appointments, the person(s) who receive(s) the greatest number of votes cast are elected. However, as required under Norwegian law, certain decisions, including resolutions to waive preferential rights to subscribe in connection with any share issue in the Company, to approve a merger or demerger of the Company, to amend the Articles of Association, to authorize an increase or reduction in the share capital, to authorize an issuance of convertible loans or warrants by the Company or to authorize the Board of Directors to purchase Shares and hold them as treasury shares or to dissolve the Company, must receive the approval of at least two-thirds of the aggregate number of votes cast as well as at least two-thirds of the share capital represented at a General Meeting. Norwegian law further requires that certain decisions, which have the effect of substantially altering the rights and preferences of any shares or class of shares, receive the approval by the holders of such shares or class of shares as well as the majority required for amending the Articles of Association.

Decisions that (i) would reduce the rights of some or all of the Company's shareholders in respect of dividend payments or other rights to assets or (ii) restrict the transferability of the Shares, require that at least 90% of the share capital represented at the General Meeting in question vote in favor of the resolution, as well as the majority required for amending the Articles of Association.

In general, only a shareholder registered in the VPS is entitled to vote for such Shares. Beneficial owners of the Shares that are registered in the name of a nominee are generally not entitled to vote under Norwegian law, nor is any person who is designated in the VPS register as the holder of such Shares as nominees. Investors should note that there are varying opinions as to the interpretation of the right to vote on nominee registered shares. In the Company's view, a nominee may not meet or vote for Shares registered on a nominee account. A shareholder must, in order to be eligible to register, meet and vote for such Shares at the General Meeting, transfer the Shares from such nominee account to an account in the shareholder's name.

There are no quorum requirements that apply to the general meetings.

8.3.3 Additional issuances and preferential rights

If the Company issues any new Shares, including bonus share issues, the Articles of Association must be amended, which requires the same vote as other amendments to the Articles of Association. In addition, under Norwegian law, the Company's shareholders have a preferential right to subscribe for new Shares issued by the Company. Preferential rights may be derogated from by resolution in a General Meeting passed by the same vote required to amend the Articles of Association. A derogation of the shareholders' preferential rights in respect of bonus issues requires the approval of all outstanding Shares. Existing shareholders who do not participate in an issuance of new Shares, including bonus shares, will be diluted.

The General Meeting may, by the same vote as is required for amending the Articles of Association, authorize the Board of Directors to issue new Shares, and to derogate from the preferential rights of shareholders in connection with such issuances. Such authorization may be effective for a maximum of two years, and the nominal value of the Shares to be issued may not exceed 50% of the registered par share capital when the authorization is registered with the Norwegian Register of Business Enterprises.

Under Norwegian law, the Company may increase its share capital by a bonus share issue, subject to approval by the Company's shareholders, by transfer from the Company's distributable equity or from the Company's share premium reserve and thus the share capital increase does not require any payment of a subscription price by the shareholders. Any bonus issues may be affected either by issuing new shares to the Company's existing shareholders or by increasing the nominal value of the Company's outstanding Shares.

Issuance of new Shares to shareholders who are citizens or residents of the United States upon the exercise of preferential rights may require the Company to file a registration statement in the United States under United States securities laws. Should the Company in such a situation decide not to file a registration statement, the Company's U.S. shareholders may not be able to exercise their preferential rights. If a U.S. shareholder is ineligible to participate in a rights offering, such shareholder would not receive the rights at all and the rights would be sold on the shareholder's behalf by the Company. Shareholders in other jurisdictions outside Norway may be similarly affected if the rights and the new Shares offered have not been registered with, or approved by, the relevant authorities in such jurisdiction. The Company has currently not filed a registration statement under the U.S. Securities Act or sought approvals under the laws of any other jurisdiction outside Norway in respect of any pre-emptive rights or the Shares, and does not intend to do so and doing so in the future may be impractical and costly. To the extent that the Company's shareholders are not able to exercise their rights to subscribe for new shares or receive or trade subscription rights, the value of such rights will be lost and such shareholders' proportional ownership interests in the Company may be reduced.

8.3.4 Minority rights

Norwegian law sets forth a number of protections for minority shareholders of the Company, including, but not limited to, those described in this paragraph and the description of General Meetings as set out above. Any of the Company's shareholders may petition Norwegian courts to have a decision of the Board of Directors or the Company's shareholders made at the General Meeting declared invalid on the grounds that it unreasonably favors certain shareholders or third parties to the detriment of other shareholders or the Company itself. The Company's shareholders may also petition the courts to dissolve the Company as a result of such decisions to the extent particularly strong reasons are considered by the court to make necessary dissolution of the Company.

Minority shareholders holding 5% or more of the Company's share capital have a right to demand in writing that the Company's Board of Directors convene an extraordinary General Meeting to discuss or resolve specific matters. In addition, any of the Company's shareholders may in writing demand that the Company place an item on the agenda for any General Meeting as long as the Company is notified in time for such item to be included in the notice of the meeting. If the notice has been issued when such a written demand is presented, a renewed notice must be issued if the deadline for issuing notice of the General Meeting has not expired.

8.3.5 Rights of redemption and repurchase of Shares

The share capital of the Company may be reduced by reducing the nominal value of the Shares or by cancelling Shares. Such a decision requires the approval of at least two-thirds of the aggregate number of votes cast and at least two-thirds of the share capital represented at a General Meeting. Redemption of individual Shares requires the consent of the holders of the Shares to be redeemed.

The Company may purchase its own Shares provided that the Board of Directors has been granted an authorization to do so by the General Meeting with the approval of at least two-thirds of the aggregate number of votes cast and at least two-thirds of the share capital represented at the General Meeting. The aggregate nominal value of treasury shares so acquired, and held by the Company must not exceed 10% of the Company's share capital, and treasury shares may only be acquired if the Company's distributable equity, according to the latest adopted balance sheet, exceeds the consideration to be paid for the Shares. The authorization by the General Meeting of the Company's shareholders cannot be granted for a period exceeding 24 months.

8.3.6 Shareholder vote on certain reorganizations

A decision of the Company's shareholders to merge with another company or to demerge requires a resolution by the General Meeting passed by at least two-thirds of the aggregate votes cast and at least two-thirds of the share capital

represented at the General Meeting. A merger plan or demerger plan signed by the Board of Directors along with certain other required documentation, would have to be sent to the Company's shareholders, or if the Articles of Association stipulate that, made available to the shareholders on the Company's website, at least one month prior to the General Meeting to pass upon the matter.

8.3.7 Liability of members of the Board of Directors

Board Members owe a fiduciary duty to the Company and its shareholders. Such fiduciary duty requires that the Board Members act in the best interests of the Company when exercising their functions and exercise a general duty of loyalty and care towards the Company. Their principal task is to safeguard the interests of the Company.

Board Members may each be held liable for any damage they negligently or willfully cause the Company. Norwegian law permits the General Meeting to discharge any such person from liability, but such discharge is not binding on the Company if substantially correct and complete information was not provided at the General Meeting passing upon the matter. If a resolution to discharge the Company's Board Members from liability or not to pursue claims against such a person has been passed by a General Meeting with a smaller majority than that required to amend the Articles of Association, shareholders representing more than 10% of the share capital or, if there are more than 100 shareholders, more than 10% of the shareholders may pursue the claim on the Company's behalf and in its name. The cost of any such action is not the Company's responsibility but can be recovered from any proceeds the Company receives as a result of the action. If the decision to discharge any of the Company's Board Members from liability or not to pursue claims against the Company's Board Members is made by such a majority as is necessary to amend the Articles of Association, the minority shareholders of the Company cannot pursue such claim in the Company's name.

8.3.8 Indemnification of Directors

Neither Norwegian law nor the Articles of Association contain any provision concerning indemnification by the Company of the Board of Directors. The Company is permitted to purchase insurance for the Board Members against certain liabilities that they may incur in their capacity as such.

8.3.9 Distribution of assets on liquidation

Under Norwegian law, the Company may be wound-up by a resolution of the Company's shareholders at the General Meeting passed by at least two-thirds of the aggregate votes cast and at least two-thirds of the share capital represented at the meeting. In the event of liquidation, the Shares rank equally in the event of a return on capital.

9 SECURITIES TRADING IN NORWAY

Set out below is a summary of certain aspects of securities trading in Norway and the possible implications of owning tradable securities on the Oslo Stock Exchange. The summary is based on the rules and regulations in force in Norway as at the date of this Securities Note, which may be subject to changes occurring after such date. This summary does not purport to be a comprehensive description of securities trading in Norway. Investors who wish to clarify aspects of securities trading in Norway should consult with and rely upon their own advisors

9.1 Introduction

The Oslo Stock Exchange was established in 1819 and offers the only regulated market for securities trading in Norway. Oslo Børs ASA is 100% owned by Euronext Nordics Holding AS, a holding company established by Euronext N.V following its acquisition of Oslo Børs VPS Holding ASA in June 2019. Euronext is a pan-European stock exchange with its registered office in Amsterdam and corporate headquarters at La Défense in Greater Paris. Euronext owns seven regulated markets across Europe, being Amsterdam, Brussels, Dublin, Lisbon, London, Oslo and Paris.

9.2 Market value of the Shares

The market value of all shares listed on the Oslo Stock Exchange, including the Shares, may fluctuate significantly, which could cause investors to lose a significant part of their investment. The market value of listed shares could fluctuate significantly in response to a number of factors beyond the respective issuer's control, including quarterly variations in operating results, adverse business developments, changes in financial estimates and investment recommendations or ratings by securities analysts, announcements by the respective issuer or its competitors of new product and service offerings, significant contracts, acquisitions or strategic relationships, publicity about the issuer, its products and services or its competitors, lawsuits against the issuer, unforeseen liabilities, changes in management, changes to the regulatory environment in which the issuer operates or general market conditions.

Furthermore, future issuances of shares or other securities may dilute the holdings of shareholders and could materially affect the price of the shares. Any issuer, including the Company, may in the future decide to offer additional shares or other securities to finance new capital-intensive projects, in connection with unanticipated liabilities or expenses or for any other purposes, including for refinancing purposes. There are no assurances that any of the issuers on the Oslo Stock Exchange will not decide to conduct further offerings of securities in the future. Depending on the structure of any future offering, certain existing shareholders may not have the ability to purchase additional equity securities. If a listed company raises additional funds by issuing additional equity securities, the holdings and voting interests of existing shareholders could be diluted, and thereby affect the share price.

9.3 Trading and settlement

Trading of equities on the Oslo Stock Exchange is carried out in Euronext's electronic trading system Optiq®. This trading system is in use by all markets operated by Euronext.

Official trading on the Oslo Stock Exchange takes place between 09:00 hours (CET/CEST) and 16:20 hours (CET/CEST) each trading day, with pre-trade period between 07:15 hours (CET/CEST) and 09:00 hours (CET/CEST), a closing auction from 16:20 hours (CET/CEST) to 16:25 hours (CET/CEST) and a trading at last period from 16:25 hours (CET/CEST) to 16:30 hours (CET/CEST). Reporting of Off-Book On Exchange trades can be done from 07:15 hours (CET/CEST) to 18:00 hours (CET/CEST).

The settlement period for trading on the Oslo Stock Exchange is two trading days (T+2). This means that securities will be settled on the investor's account in VPS two trading days after the transaction, and that the seller will receive payment after two trading days.

The Oslo Stock Exchange offers an interoperability model for clearing and counterparty services for equity trading through LCH Limited, EuroCCP and Six X-Clear.

Investment services in Norway may only be provided by Norwegian investment firms holding a license under the Norwegian Securities Trading Act, branches of investment firms from an EEA member state or investment firms from outside the EEA that have been licensed to operate in Norway. Investment firms in an EEA member state may also provide cross-border investment services into Norway.

It is possible for investment firms to undertake market-making activities in shares listed in Norway if they have a license to this effect under the Norwegian Securities Trading Act, or in the case of investment firms in an EEA member state, a license to carry out market-making activities in their home jurisdiction. Such market-making activities will be governed by the regulations of the Norwegian Securities Trading Act relating to brokers' trading for their own account. However, such market-making activities do not as such require notification to the Norwegian FSA or the Oslo Stock Exchange except for the general obligation of investment firms that are members of the Oslo Stock Exchange to report all trades in stock exchange listed securities.

9.4 Information, control and surveillance

Under Norwegian law, the Oslo Stock Exchange is required to perform a number of surveillance and control functions. The Surveillance and Corporate Control unit of the Oslo Stock Exchange monitors all market activity on a continuous basis. Market surveillance systems are largely automated, promptly warning department personnel of abnormal market developments.

The Norwegian FSA controls the issuance of securities in both the equity and bond markets in Norway and evaluates whether the issuance documentation contains the required information and whether it would otherwise be unlawful to carry out the issuance.

Under Norwegian law, a company that is listed on a Norwegian regulated market, or has applied for listing on such market, must promptly release any inside information directly concerning the company. Inside information means precise information about financial instruments, the issuer thereof or other matters which are likely to have a significant effect on the price of the relevant financial instruments or related financial instruments, and which are not publicly available or commonly known in the market. A company may, however, delay the release of such information in order not to prejudice its legitimate interests, provided that it is able to ensure the confidentiality of the information and that the delayed release would not be likely to mislead the public. The Oslo Stock Exchange may levy fines on companies violating these requirements.

9.5 The VPS and transfer of shares

The Company's principal share register is operated through the VPS. The VPS is the Norwegian paperless centralized securities register. It is a computerized book-keeping system in which the ownership of, and all transactions relating to, Norwegian listed shares must be recorded. The VPS and the Oslo Stock Exchange are both wholly-owned by Euronext Nordics Holding AS.

All transactions relating to securities registered with the VPS are made through computerized book entries. No physical share certificates are, or may be, issued. The VPS confirms each entry by sending a transcript to the registered shareholder irrespective of any beneficial ownership. To give effect to such entries, the individual shareholder must establish a share account with a Norwegian account agent. Norwegian banks, Norges Bank (being, Norway's central bank), authorized securities brokers in Norway and Norwegian branches of credit institutions established within the EEA are allowed to act as account agents.

As a matter of Norwegian law, the entry of a transaction in the VPS is *prima facie* evidence in determining the legal rights of parties as against the issuing company or any third party claiming an interest in the given security. A transferee or assignee of shares may not exercise the rights of a shareholder with respect to such shares unless such transferee or assignee has registered such shareholding or has reported and shown evidence of such share acquisition, and the acquisition is not prevented by law, the relevant company's articles of association or otherwise.

The VPS is liable for any loss suffered as a result of faulty registration or an amendment to, or deletion of, rights in respect of registered securities unless the error is caused by matters outside the VPS' control which the VPS could not reasonably be expected to avoid or overcome the consequences of. Damages payable by the VPS may, however, be reduced in the event of contributory negligence by the aggrieved party.

The VPS must provide information to the Norwegian FSA on an ongoing basis, as well as any information that the Norwegian FSA requests. Further, Norwegian tax authorities may require certain information from the VPS regarding any individual's holdings of securities, including information about dividends and interest payments.

9.6 Shareholder register – Norwegian law

Under Norwegian law, shares are registered in the name of the beneficial owner of the shares. Beneficial owners of the shares that are registered in a nominee account (such as through brokers, dealers or other third parties) may not be able to vote for such shares unless their ownership is re-registered in their names with the VPS prior to any general meeting. As a general rule, there are no arrangements for nominee registration and Norwegian shareholders are not allowed to register their shares in the VPS through a nominee. However, foreign shareholders may register their shares in the VPS in the name of a nominee (bank or other nominee) approved by the Norwegian FSA. An approved and registered nominee has a duty to provide information on demand about beneficial shareholders to the company and to the Norwegian authorities. In case of registration by nominees, the registration in the VPS must show that the registered owner is a nominee. A registered nominee has the right to receive dividends and other distributions, but cannot vote in general meetings on behalf of the beneficial owners. There is no assurance that beneficial owners of the Shares will receive the notice of any General Meeting in time to instruct their nominees to either effect a re-registration of their Shares or otherwise vote for their Shares in the manner desired by such beneficial owners. See Section 8.3.2 "Voting rights – Amendments of the Articles of Association" for more information on nominee accounts.

9.7 Foreign investment in shares listed in Norway

Foreign investors may trade shares listed on the Oslo Stock Exchange through any broker that is a member of the Oslo Stock Exchange, whether Norwegian or foreign.

Foreign investors should note that the rights of holders of shares listed on the Oslo Stock Exchange and issued by Norwegian incorporated companies are governed by Norwegian law and by the respective company's articles of association. These rights may differ from the rights of shareholders in other jurisdictions. In particular, Norwegian law limits the circumstances under which shareholders of Norwegian companies may bring derivative actions. For instance, under Norwegian law, any action brought by a company in respect of wrongful acts committed against such company will be prioritised over actions brought by shareholders claiming compensation in respect of such acts. In addition, it may be difficult to prevail in a claim against the company under, or to enforce liabilities predicated upon, securities laws in other jurisdictions. See Section 8.3 "Certain aspects of Norwegian corporate law" for more information on certain aspects of Norwegian law.

9.8 Disclosure obligations

If a person's, entity's or consolidated group's proportion of the total issued shares and/or rights to shares in a company listed on a regulated market in Norway (with Norway as its home state, which will be the case for the Company) reaches, exceeds or falls below the respective thresholds of 5%, 10%, 15%, 20%, 25%, 1/3, 50%, 2/3 or 90% of the share capital or the voting rights of that company, the person, entity or group in question has an obligation under the Norwegian Securities Trading Act to notify the Oslo Stock Exchange and the issuer immediately. The same applies if the disclosure thresholds are passed due to other circumstances, such as a change in the company's share capital.

9.9 Insider trading

According to Norwegian law, subscription for, purchase, sale or exchange or other acquisitions or disposals of financial instruments that are listed, or subject to the application for listing, on a Norwegian regulated market, or incitement to such dispositions, must not be undertaken by anyone who has inside information, as defined in Article 7 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, and as implemented in Norway in accordance with Section 3-1 of the Norwegian Securities Trading Act. The same applies to the entry into, purchase, sale or exchange of options or futures/forward contracts or equivalent rights whose value or price either depends on or has an effect on the price or value of such financial instruments or incitement to such dispositions.

9.10 Mandatory offer requirement

The Norwegian Securities Trading Act requires any person, entity or consolidated group that becomes the owner of shares representing more than one-third (or more than 40% or 50%) of the voting rights of a company listed on a Norwegian regulated market (with the exception of certain foreign companies) to, within four weeks, make an unconditional general offer for the purchase of the remaining shares in that company. A mandatory offer obligation may also be triggered where a party acquires the right to become the owner of shares that, together with the party's own

shareholding, represent more than one-third (or more than 40% or 50% as applicable) of the voting rights in the company and the Oslo Stock Exchange decides that this is regarded as an effective acquisition of the shares in question.

The mandatory offer obligation ceases to apply if the person, entity or consolidated group sells the portion of the shares that exceeds the relevant threshold within four weeks of the date on which the mandatory offer obligation was triggered.

When a mandatory offer obligation is triggered, the person subject to the obligation is required to immediately notify the Oslo Stock Exchange and the company in question accordingly. The notification is required to state whether an offer will be made to acquire the remaining shares in the company or whether a sale will take place. As a rule, a notification to the effect that an offer will be made cannot be retracted. The offer and the offer document required are subject to approval by the Oslo Stock Exchange before the offer is submitted to the shareholders or made public.

The offer price per share must be at least as high as the highest price paid or agreed by the offeror for the shares in the six-month period prior to the date the threshold was exceeded. If the acquirer acquires or agrees to acquire additional shares at a higher price prior to the expiration of the mandatory offer period, the acquirer is obliged to restate its offer at such higher price. A mandatory offer must be in cash or contain a cash alternative at least equivalent to any other consideration offered.

In case of failure to make a mandatory offer or to sell the portion of the shares that exceeds the relevant threshold within four weeks, the Oslo Stock Exchange may force the acquirer to sell the shares exceeding the threshold by public auction. Moreover, a shareholder who fails to make an offer may not, as long as the mandatory offer obligation remains in force, exercise rights in the company, such as voting in a general meeting, without the consent of a majority of the remaining shareholders. The shareholder may, however, exercise his/her/its rights to dividends and pre-emption rights in the event of a share capital increase. If the shareholder neglects his/her/its duty to make a mandatory offer, the Oslo Stock Exchange may impose a cumulative daily fine that runs until the circumstance has been rectified.

Any person, entity or consolidated group that owns shares representing more than one-third of the votes in a company listed on a Norwegian regulated market (with the exception of certain foreign companies) is obliged to make an offer to purchase the remaining shares of the company (repeated offer obligation) if the person, entity or consolidated group through acquisition becomes the owner of shares representing 40%, or more of the votes in the company. The same applies correspondingly if the person, entity or consolidated group through acquisition becomes the owner of shares representing 50% or more of the votes in the company. The mandatory offer obligation ceases to apply if the person, entity or consolidated group sells the portion of the shares which exceeds the relevant threshold within four weeks of the date on which the mandatory offer obligation was triggered.

Any person, entity or consolidated group that has passed any of the above mentioned thresholds in such a way as not to trigger the mandatory bid obligation, and has therefore not previously made an offer for the remaining shares in the company in accordance with the mandatory offer rules is, as a main rule, obliged to make a mandatory offer in the event of a subsequent acquisition of shares in the company.

9.11 Compulsory acquisition

Pursuant to the Norwegian Public Limited Companies Act and the Norwegian Securities Trading Act, a shareholder who, directly or through subsidiaries, acquires shares representing 90% or more of the total number of issued shares in a Norwegian public limited liability company, as well as 90% or more of the total voting rights, has a right, and each remaining minority shareholder of the company has a right to require such majority shareholder, to effect a compulsory acquisition for cash of the shares not already owned by such majority shareholder. Through such compulsory acquisition the majority shareholder becomes the owner of the remaining shares with immediate effect.

If a shareholder acquires shares representing more than 90% of the total number of issued shares, as well as more than 90% of the total voting rights, through a voluntary offer in accordance with the Securities Trading Act, a compulsory acquisition can, subject to the following conditions, be carried out without such shareholder being obliged to make a mandatory offer: (i) the compulsory acquisition is commenced no later than four weeks after the acquisition of shares through the voluntary offer, (ii) the price offered per share is equal to or higher than what the offer price would have been in a mandatory offer, and (iii) the settlement is guaranteed by a financial institution authorized to provide such guarantees in Norway.

A majority shareholder who effects a compulsory acquisition is required to offer the minority shareholders a specific price per share, the determination of which is at the discretion of the majority shareholder. However, where the offeror,

after making a mandatory or voluntary offer, has acquired more than 90% of the voting shares of a company and a corresponding proportion of the votes that can be cast at the general meeting, and the offeror pursuant to section 4-25 of the Norwegian Public Limited Companies Act completes a compulsory acquisition of the remaining shares within three months after the expiry of the offer period, it follows from the Norwegian Securities Trading Act that the redemption price shall be determined on the basis of the offer price for the mandatory/voluntary offer unless specific reasons indicate another price.

Should any minority shareholder not accept the offered price, such minority shareholder may, within a specified deadline of not less than two months, request that the price be set by a Norwegian court. The cost of such court procedure will, as a general rule, be the responsibility of the majority shareholder, and the relevant court will have full discretion in determining the consideration to be paid to the minority shareholder as a result of the compulsory acquisition.

Absent a request for a Norwegian court to set the price or any other objection to the price being offered, the minority shareholders would be deemed to have accepted the offered price after the expiry of the specified deadline.

9.12 Foreign exchange controls

There are currently no foreign exchange control restrictions in Norway that would potentially restrict the payment of dividends to a shareholder outside Norway, and there are currently no restrictions that would affect the right of shareholders of a company that has its shares registered with the VPS who are not residents in Norway to dispose of their shares and receive the proceeds from a disposal outside Norway. There is no maximum transferable amount either to or from Norway, although transferring banks are required to submit reports on foreign currency exchange transactions into and out of Norway into a central data register maintained by the Norwegian customs and excise authorities. The Norwegian police, tax authorities, customs and excise authorities, the National Insurance Administration and the Norwegian FSA have electronic access to the data in this register.

10 TAXATION

10.1 Norwegian taxation

Set out below is a summary of certain Norwegian tax matters related to an investment in the Company. The summary regarding Norwegian taxation is based on the laws in force in Norway as at the date of this Securities Note, which may be subject to any changes in law occurring after such date. Such changes could possibly be made on a retrospective basis.

The following summary does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to purchase, own or dispose of the Shares in the Company. Shareholders who wish to clarify their own tax situation should consult with and rely upon their own tax advisors. Shareholders resident in jurisdictions other than Norway and shareholders who cease to be resident in Norway for tax purposes (due to domestic tax law or tax treaty) should specifically consult with and rely upon their own tax advisors with respect to the tax position in their country of residence and the tax consequences related to ceasing to be resident in Norway for tax purposes.

Please note that for the purpose of the summary below, a reference to a Norwegian or non-Norwegian shareholder refers to the tax residency rather than the nationality of the shareholder.

The tax legislation in the Company's jurisdiction of incorporation and the tax legislation in the jurisdictions in which the shareholders are resident for tax purposes may have an impact on the income received from the Shares.

10.1.1 Taxation of dividends

Norwegian Personal Shareholders

Dividends distributed by the Company to shareholders who are individuals resident in Norway for tax purposes ("**Norwegian Personal Shareholders**") are taxable in Norway for such shareholders currently at an effective tax rate of 31.68% to the extent the dividend exceeds a tax-free allowance; i.e. dividends received, less the tax free allowance, shall be multiplied by 1.44 which are then included as ordinary income taxable at a flat rate of 22%, increasing the effective tax rate on dividends received by Norwegian Personal Shareholders to 31.68%. However, please note that the newly elected Norwegian Government proposed on 8 November 2021 to increase the adjustment factor from 1.44 to 1.6 with effect from 1 January 2022. If the amendment is adopted by the Norwegian Parliament, the effective tax rate on dividends received by Norwegian Personal Shareholders will be 35.2%.

The allowance is calculated on a share-by-share basis. The allowance for each share is equal to the cost price of the share multiplied by a determined risk free interest rate based on the effective rate of interest on treasury bills (Nw.: *statskasseveksler*) with three months maturity plus 0.5 percentage points, after tax. The allowance is calculated for each calendar year, and is allocated solely to Norwegian Personal Shareholders holding shares at the expiration of the relevant calendar year.

Norwegian Personal Shareholders who transfer shares will thus not be entitled to deduct any calculated allowance related to the year of transfer. Any part of the calculated allowance one year exceeding the dividend distributed on the share ("**excess allowance**") may be carried forward and set off against future dividends received on, or gains upon realization, of the same share. Any excess allowance on a share may also be added to the cost price of such share for the purposes of calculating the tax free allowance as described above.

Norwegian Personal Shareholders may hold the shares through a Norwegian share saving account (Nw.: *aksjesparekonto*). Dividends received on shares held through a share saving account will not be taxed with immediate effect. Instead, withdrawal of funds from the share saving account exceeding the paid in deposit will be regarded as taxable income, regardless of whether the funds are derived from gains or dividends related to the shares held in the account. Such income will be taxed with an effective tax rate of 31.68%, cf. above. Please note that if the proposed increase in the adjustment factor as referred to above is adopted by the Norwegian Parliament, such income will be taxed with an effective tax rate of 35.2%. Norwegian Personal Shareholders will still be entitled to a calculated tax-free allowance. Reference is made to Section 10.1.2 "Taxation of capital gains on realization of shares - Norwegian Personal Shareholders" for further information in respect of Norwegian share saving accounts.

Norwegian Corporate Shareholders

Dividends distributed by the Company to shareholders who are limited liability companies (and certain similar entities) resident in Norway for tax purposes ("**Norwegian Corporate Shareholders**"), are effectively taxed at a rate of currently 0.66% (3% of dividend income from such shares is included in the calculation of ordinary income for Norwegian

Corporate Shareholders and ordinary income is subject to tax at a flat rate of currently 22%). For Norwegian Corporate Shareholders that are considered to be "Financial Institutions" under the Norwegian financial activity tax (banks, holding companies), the effective rate of taxation for dividends is 0.75%.

Non-Norwegian Personal Shareholders

Dividends distributed by the Company to shareholders who are individuals not resident in Norway for tax purposes ("**Non-Norwegian Personal Shareholders**"), are as a general rule subject to withholding tax at a rate of 25%. The withholding tax rate of 25% is normally reduced through tax treaties between Norway and the country in which the shareholder is resident. The withholding obligation lies with the company distributing the dividends and the Company assumes this obligation.

Non-Norwegian Personal Shareholders resident within the EEA for tax purposes may apply individually to Norwegian tax authorities for a refund of an amount corresponding to the calculated tax-free allowance on each individual share, reference is made to Section 10.1.1 "Taxation of dividends – Norwegian Personal Shareholders" above. However, the deduction for the tax-free allowance does not apply in the event that the withholding tax rate, pursuant to an applicable tax treaty, leads to a lower taxation of the dividends than the withholding tax rate of 25% less the tax-free allowance.

If a Non-Norwegian Personal Shareholder is carrying on business activities in Norway and the shares are effectively connected with such activities, the shareholder will be subject to the same taxation of dividends as a Norwegian Personal Shareholder, as described above.

Non-Norwegian Personal Shareholders who have suffered a higher withholding tax than set out in an applicable tax treaty may apply to the Norwegian tax authorities for a refund of the excess withholding tax deducted.

All Non-Norwegian Personal Shareholders must document their entitlement to a reduced withholding tax rate by obtaining a certificate of residence issued by the tax authorities in the shareholder's country of residence, confirming that the shareholder is resident in that state. The documentation must be provided to either the nominee or the account operator (VPS) and cannot be older than three years.

Non-Norwegian Personal Shareholders should consult their own advisors regarding the availability of treaty benefits in respect of dividend payments, including the possibility of effectively claiming a refund of withholding tax.

Non-Norwegian Personal Shareholders resident in the EEA for tax purposes may hold their shares through a Norwegian share saving account. Dividends received on, and gains derived upon the realization of, shares held through a share saving account by a Non-Norwegian Personal Shareholder resident in the EEA will not be taxed with immediate effect. Instead, withdrawal of funds from the share saving account exceeding the Non-Norwegian Personal Shareholder's paid in deposit, will be subject to withholding tax at a rate of 25% (unless reduced pursuant to an applicable tax treaty). Capital gains realized upon realization of shares held through the share saving account will be regarded as paid in deposits, which may be withdrawn without taxation. Losses will correspondingly be deducted from the paid in deposit, reducing the amount which can be withdrawn without withholding tax.

The obligation to deduct and report withholding tax on shares held through a saving account, cf. above, lies with the account operator.

Non-Norwegian Corporate Shareholders

Dividends distributed by the Company to shareholders who are limited liability companies (and certain other entities) domiciled outside of Norway for tax purposes ("**Non-Norwegian Corporate Shareholders**"), are as a general rule subject to withholding tax at a rate of 25%. The withholding tax rate of 25% is normally reduced through tax treaties between Norway and the country in which the shareholder is resident.

Dividends distributed to Non-Norwegian Corporate Shareholders domiciled within the EEA for tax purposes are exempt from Norwegian withholding tax provided that the shareholder is the beneficial owner of the shares and that the shareholder is genuinely established and performs genuine economic business activities within the relevant EEA jurisdiction.

If a Non-Norwegian Corporate Shareholder is carrying on business activities in Norway and the shares are effectively connected with such activities, the shareholder will be subject to the same taxation of dividends as a Norwegian Corporate Shareholder, as described above.

Non-Norwegian Corporate Shareholders who have suffered a higher withholding tax than set out in an applicable tax treaty may apply to the Norwegian tax authorities for a refund of the excess withholding tax deducted. The same will apply to Non-Norwegian Corporate Shareholders who have suffered withholding tax although qualifying for the Norwegian participation exemption.

All Non-Norwegian Corporate Shareholders must document their entitlement to a reduced withholding tax rate by either (i) presenting an approved withholding tax refund application or (ii) present an approval from the Norwegian tax authorities confirming that the recipient is entitled to a reduced withholding tax rate. In addition, a certificate of residence issued by the tax authorities in the shareholder's country of residence, confirming that the shareholder is resident in that state, must be obtained. Such documentation must be provided to either the nominee or the account operator (VPS).

In order for a Non-Norwegian Corporate Shareholder resident in the EEA to be exempt from withholding tax, the company must provide all documentation mentioned above, as well as a declaration stating that the circumstances entitling the company to the exemption have not changed since the documentation was issued.

The withholding obligation in respect of dividends distributed to Non-Norwegian Corporate Shareholders and on nominee registered shares lies with the company distributing the dividends and the Company assumes this obligation.

Non-Norwegian Corporate Shareholders should consult their own advisors regarding the availability of treaty benefits in respect of dividend payments, including the possibility of effectively claiming a refund of withholding tax.

10.1.2 Taxation of capital gains on realization of shares

Norwegian Personal Shareholders

Sale, redemption or other disposal of shares is considered a realization for Norwegian tax purposes. A capital gain or loss generated by a Norwegian Personal Shareholder through a disposal of shares is taxable or tax deductible in Norway. The effective tax rate on gain or loss related to shares realized by Norwegian Personal Shareholders is currently 31.68%; i.e. capital gains (less the tax free allowance) and losses shall be multiplied by 1.44 which are then included in or deducted from the Norwegian Personal Shareholder's ordinary income in the year of disposal. Ordinary income is taxable at a flat rate of 22%, increasing the effective tax rate on gains/losses realized by Norwegian Personal Shareholders to 31.68%. Please note that if the proposed increase in the adjustment factor as referred to under Section 10.1.1 "Taxation of dividends – Norwegian Personal Shareholders" from 1.44 to 1.6 is adopted by the Norwegian Parliament, the effective tax rate on gain or loss related to shares realised by Norwegian Personal Shareholders will be 35.2%.

The gain is subject to tax and the loss is tax deductible irrespective of the duration of the ownership and the number of shares disposed of.

The taxable gain/deductible loss is calculated per share as the difference between the consideration for the share and the Norwegian Personal Shareholder's cost price of the share, including costs incurred in relation to the acquisition or realization of the share. From this capital gain, Norwegian Personal Shareholders are entitled to deduct a calculated allowance provided that such allowance has not already been used to reduce taxable dividend income. Reference is made to Section 10.1.1 "Taxation of dividends – Norwegian Personal Shareholders" above for a description of the calculation of the allowance. The allowance may only be deducted in order to reduce a taxable gain, and cannot increase or produce a deductible loss, i.e. any unused allowance exceeding the capital gain upon the realization of a share will be annulled. Unused allowance may not be set off against gains from realization of other shares.

If the Norwegian Personal Shareholder owns shares acquired at different points in time, the shares that were acquired first will be regarded as the first to be disposed of, on a first-in first-out basis.

Special rules apply for Norwegian Personal Shareholders that cease to be tax-resident in Norway.

Gains derived upon the realization of shares held through a share saving account will be exempt from immediate Norwegian taxation and losses will not be tax deductible. Instead, withdrawal of funds from the share saving account exceeding the Norwegian Personal Shareholder's paid in deposit, will be regarded as taxable income, subject to tax at an effective tax rate of 31.68%. Please note that if the proposed increase in the adjustment factor as referred to under Section 10.1.1 "Taxation of dividends – Norwegian Personal Shareholders" from 1.44 to 1.6 is implemented, such income will be taxed with an effective tax rate of 35.2%. Norwegian Personal Shareholders will be entitled to a calculated tax-free allowance provided that such allowance has not already been used to reduce taxable dividend income, reference is

made to Section 10.1.1 "Taxation of dividends – Norwegian Personal Shareholders" above. The tax-free allowance is calculated based on the lowest paid in deposit in the account during the income year, plus any unused tax-free allowance from previous years. The tax-free allowance can only be deducted in order to reduce taxable income, and cannot increase or produce a deductible loss. Any excess allowance may be carried forward and set off against future withdrawals from the account or future dividends received on shares held through the account.

Norwegian Personal Shareholders holding shares through more than one share saving account may transfer their shares or securities between the share saving accounts without incurring Norwegian taxation.

Norwegian Corporate Shareholders

Norwegian Corporate Shareholders are exempt from tax on capital gains derived from the realization of shares qualifying for participation exemption, including shares in the Company. Losses upon the realization and costs incurred in connection with the purchase and realization of such shares are not deductible for tax purposes.

Special rules apply for Norwegian Corporate Shareholders that cease to be tax-resident in Norway.

Non-Norwegian Personal Shareholders

Gains from the sale or other disposal of shares by a Non-Norwegian Personal Shareholder will not be subject to taxation in Norway unless the Non-Norwegian Personal Shareholder holds the shares in connection with business activities carried out or managed from Norway.

Reference is made to Section 10.1.1 "Taxation of dividends – Non-Norwegian Personal Shareholders" above for a description of the availability of a Norwegian share saving accounts.

Non-Norwegian Corporate Shareholders

Capital gains derived by the sale or other realization of shares by Non-Norwegian Corporate Shareholders are not subject to taxation in Norway unless the shareholding is effectively connected with business activities carried out in or managed from Norway.

10.1.3 Taxation of Subscription Rights

Norwegian Personal Shareholders

A Norwegian Personal Shareholder's subscription for shares pursuant to a subscription right is not subject to taxation in Norway. Costs related to the subscription for the shares, including the purchase price for any purchased subscription rights, will be added to the cost price of the shares.

Sale and other transfer of subscription rights are considered a realization for Norwegian tax purposes. A capital gain or loss generated by a Norwegian Personal Shareholder through a realization of subscription rights is taxable or tax deductible in Norway and subject to the same taxation as a capital gain or loss generated through realization of shares, reference is made to Section 10.1.2 "Taxation of capital gains on realization of shares" above.

Subscription rights acquired as a consequence of ownership of shares held on a share savings account may be held on the share savings account, reference is made to Section 10.1.2 "Taxation of capital gains on realization of shares – Norwegian Personal Shareholders" above, but will not be covered by the tax exemption.

Norwegian Corporate shareholders

A Norwegian Corporate Shareholder's subscription for shares pursuant to a subscription right is not subject to taxation in Norway. Costs related to the subscription for the shares will be added to the cost price of the shares including the purchase price for any purchased subscription rights.

Sale and other transfer of subscription rights are considered a realization for Norwegian tax purposes. Norwegian Corporate Shareholders are exempt from tax on capital gains derived from the realization of subscription rights qualifying for the Norwegian participation exemption. Losses upon the realization and costs incurred in connection with the purchase and realization of such subscription rights are not deductible for tax purposes.

Non-Norwegian Shareholders

A Non-Norwegian (Personal or Corporate) Shareholder's subscription for shares pursuant to a subscription right is not subject to taxation in Norway.

Capital gains derived by the sale or other transfer of subscription rights by Non-Norwegian Shareholders are not subject to taxation in Norway unless the Non-Norwegian Shareholder holds the subscription rights in connection with business activities carried out or managed from Norway. Such taxation may be limited according to an applicable tax treaty or other specific regulations.

Note that capital gains related to subscription rights are not comprised by the Norwegian share saving account scheme for Non-Norwegian Personal Shareholders resident within the EEA as further described above in Section 10.1.2 "Taxation of capital gains on realization of shares – Norwegian Personal Shareholders" above.

10.1.4 Net wealth tax

The value of shares is included in the basis for the computation of net wealth tax imposed on Norwegian Personal Shareholders. Currently, the marginal net wealth tax rate is 0.85% of the value assessed. Please note that the Norwegian Government proposed on 8 November 2021 that the marginal net wealth tax rate is increased by 0.1% to 0.95% with effect from 1 January 2022. The value for assessment purposes for listed shares is equal to 55% of the listed value as of 1 January in the year of assessment (i.e. the year following the relevant fiscal year). The value of debt allocated to the listed shares for Norwegian wealth tax purposes is reduced correspondingly (i.e. to 55%). Please note that the Norwegian Government also proposed on 8 November 2021 to increase the value for assessment purposes to 65% of the value of the Shares included in the basis for the computation of net wealth tax imposed on Norwegian Individual Shareholders. It is further proposed that the value for assessment purposes for debt allocated to the Shares shall be reduced correspondingly. If the proposals are adopted by the Norwegian Parliament, the amendments will be effective as of 1 January 2022. Norwegian Corporate Shareholders are not subject to net wealth tax..

Non-Norwegian (Personal and Corporate) Shareholders are generally not subject to Norwegian net wealth tax. Non-Norwegian Personal Shareholders can, however, be taxable if the shareholding is effectively connected to the conduct of trade or business in Norway.

10.1.5 VAT and transfer taxes

No VAT, stamp or similar duties are currently imposed in Norway on the transfer or issuance of shares and subscription rights.

10.1.6 Inheritance tax

A transfer of shares or subscription rights through inheritance or as a gift does not give rise to inheritance or gift tax in Norway.

11 THE TERMS OF THE RIGHTS ISSUE

11.1 Overview

The Rights Issue consists of an offer by the Company of 101,744,186 Offer Shares, each with a par value of NOK 0.10, at a Subscription Price of NOK 1.72 per Offer Share, thereby raising gross proceeds of approximately NOK 175 million.

Existing Shareholders will be granted tradable Subscription Rights that, subject to applicable law, provide a preferential right to subscribe for, and be allocated, Offer Shares at the Subscription Price in the Rights Issue. Over-subscription and subscription without Subscription Rights are permitted but there can be no assurance that Offer Shares will be allocated for such subscriptions.

The total gross proceeds of the Rights Issue is fully underwritten through a combination of i) pro rata subscriptions by the existing shareholder AP4 (The Fourth Swedish National Pension Fund), and ii) by the Underwriters pursuant to, and subject to, the limitations in, the Underwriting Agreement, as further described in Section 11.23 "The Underwriting" below.

The Offer Shares allocated in the Rights Issue are expected to be traded on the Oslo Stock Exchange from and including 22 December 2021.

The Subscription Rights and the Offer Shares have not been, and will not be, registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction in the United States, and are being offered and sold: (i) in the United States only to QIBs as defined in Rule 144A pursuant to transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions" as defined in, and in compliance with, Regulation S.

This Securities Note does not constitute an offer of, or an invitation to purchase or subscribe, the Offer Shares and/or the use of the Subscription Rights to subscribe for Offer Shares in any jurisdiction in which such offer or sale would be unlawful. For further details, see "Important information" and Section 12 "Selling and Transfer Restrictions".

11.2 Resolution to issue the Offer Shares

On 25 November 2021, the extraordinary general meeting of the Company passed the following resolution to increase the Company's share capital and issue the Offer Shares in connection with the Rights Issue (translated from Norwegian):

- (i) *The share capital is increased with NOK 10,174,418.60 by the issuance of 101,744,186 new shares, each with a nominal value of NOK 0.10.*
- (ii) *The subscription price is NOK 1.72 per share.*
- (iii) *Shareholders of the Company as of 25 November 2021 as registered as such in the Company's shareholders' register in the Norwegian Central Securities Depository (the "VPS") on 29 November 2021 (the "Record Date") (cf. the two days' settlement procedure of the VPS) shall have a preferential right to subscribe for and be allocated the new shares in proportion to their shareholding in the Company, cf. Section 10-4 (1) of the Norwegian Public Limited Companies Act*
- (iv) *Tradeable subscription rights will be issued and the subscription rights shall be registered in the VPS. The subscription rights shall be tradeable from and including the first day of the subscription period and until 16:30 (Oslo time) two trading days prior to the end of the subscription period. Over-subscription and subscription without subscription rights is permitted.*
- (v) *The Company shall prepare a prospectus in connection with the rights issue, which shall be approved by the Norwegian Financial Supervisory Authority. Unless the board of directors decides otherwise, the prospectus shall not be registered with or approved by any foreign prospectus authority. The new shares may not be subscribed for by an investor in jurisdictions where such subscription is not permitted or to whom the new shares cannot lawfully be offered without a prospectus or similar documentation. The Company, or anyone appointed or instructed by the Company, shall have the right to (but no obligation), for shareholders who in the Company's opinion are not entitled to subscribe for new shares due to limitations set out in law or other regulations in the jurisdiction where such shareholder is resident or a citizen, sell the relevant shareholder's subscription rights against transfer of the net proceeds from such sale to the shareholder.*

- (vi) *The subscription period shall commence on 30 November 2021 and expire at 16:30 (Oslo time) on 14 December 2021. If the prospectus is not approved in time to uphold this subscription period, the subscription period shall commence on the second trading day on the Oslo Stock Exchange following the approval and expire at 16:30 hours (Oslo time) two weeks thereafter. The subscription period may not be shortened, but the board of directors may extend the subscription period if this is required by law due to the publication of a supplement prospectus. Shares that are not subscribed for by the expiry of the subscription period, and which shall be subscribed for by and allocated to the underwriters in the rights issue, shall be subscribed for by such underwriters within four trading days following expiry of the subscription period. Subscription for shares shall be made on a separate subscription form prior to the subscription deadline.*
- (vii) *The subscription amount shall be paid in cash. Payment for the new shares shall be made on or prior to 17 December 2021, or the fourth trading day on the Oslo Stock Exchange after the expiry of the subscription period if the subscription period is postponed according to subparagraph (vi) above. Subscribers who have a Norwegian bank account must, and will by signing the subscription form, give a one-time irrevocable authorisation to debit a specified Norwegian bank account for the amount payable for the shares which are allocated to the subscriber. The amount will be debited from the specified bank account on or around the payment date. Subscribers who do not have a Norwegian bank account must ensure that payment with cleared funds for the new shares allocated to them is received on or before the payment date.*
- (viii) *The new shares shall be allocated by the board of directors. The following allocation criteria shall apply:*
- a) *Allocation of shares to subscribers will be made in accordance with granted and acquired subscription rights which have been validly exercised during the subscription period. Each subscription right will give the right to subscribe and be allocated one (1) new share in the rights issue..*
- b) *Any unallocated new shares following the allocation under item (a) above shall be allocated to those underwriters who have subscribed New Shares in the subscription period, limited upwards to their respective underwriting obligation*
- c) *If not all subscription rights are validly exercised during the subscription period and there are remaining unallocated new shares following the allocation to the underwriters who have subscribed new shares in the subscription period pursuant to items (a) and (b) above, subscribers who have exercised their subscription rights and over-subscribed, will be allocated additional new shares on a pro rata basis based on the number of subscription rights exercised by each subscriber. To the extent that pro rata allocation is not possible, the Company will determine the allocation by drawing of lots.*
- d) *New shares not allocated pursuant to item (viii) a) to c) above, will be allocated to subscribers not holding subscription rights. Allocation will be sought made on a pro rata basis based on their respective subscription amounts.*
- e) *New shares not allocated pursuant to item (viii) a) to d) above will be subscribed by and allocated to the underwriters in the rights issue pursuant to, and in accordance with, the individual underwriter's underwriting commitments.*
- (ix) *The new shares will carry full rights in the Company, including the right to dividend, from the time of the registration of the share capital increase with the Norwegian Register of Business Enterprises.*
- (x) *Section 4 of the Company's articles of association will be amended to reflect the new share capital and the new number of shares following the share capital increase.*
- (xi) *Shares which have not been subscribed by and allocated to other subscribers in the rights issue at the expiry of the subscription period, shall be allocated to the underwriters listed in a separate appendix pursuant to their respective underwriting commitments in the underwriting for the rights issue. The underwriters' underwriting commitment is made on a pro rata basis, based on their respective underwritten amount and is subject to certain customary conditions for such commitments.*
- (xii) *The costs payable by the Company in connection with the share capital increase are for the time being estimated to be NOK 25 million, including an underwriting commission of NOK 14 million for the underwriting commitment.*

11.3 Conditions for completion of the Rights Issue

The completion of the Rights Issue is subject to the condition that the Underwriting Agreement remains in full force and effect if required in order to raise the gross proceeds. See Section 11.23 "The Underwriting" below for a description of the underwriting and the Underwriting Agreement, including the conditions and termination rights to which the underwriting is subject.

If it becomes clear that the condition mentioned above will not be fulfilled, the Rights Issue will be withdrawn.

Further, the Rights Issue may be withdrawn, or the completion of the Rights Issued may be delayed, if the aggregate subscription amount for the Offer Shares is not received by the Company on time or at all.

If the Rights Issue is withdrawn, all Subscription Rights will lapse without value, any subscriptions for, and allocations of, Offer Shares that have been made will be disregarded and any payments for Offer Shares made will be returned to the subscribers without interest or any other compensation. The lapsing of Subscription Rights shall be without prejudice to the validity of any trades in Subscription Rights, and investors will not receive any refund or compensation in respect of Subscription Rights purchased in the market.

11.4 Timetable

The timetable set out below provides certain indicative key dates for the Rights Issue:

Last day of trading in the Shares including Subscription Rights.....	25 November 2021
First day of trading in the Shares excluding Subscription Rights.....	26 November 2021
Record Date.....	29 November 2021
Subscription Period commences	30 November 2021 at 09:00 hours (CET)
Trading in Subscription Rights commences on the Oslo Stock Exchange	30 November 2021 at 09:00 hours (CET)
Trading in Subscription Rights ends	10 December 2021 at 16:30 hours (CET)
Subscription Period ends	14 December 2021 at 16:30 hours (CET)
Allocation of the Offer Shares.....	Expected on or about 15 December 2021
Distribution of allocation letters	Expected on or about 15 December 2021
Payment Date	Expected on or about 17 December 2021
Registration of the share capital increase with the Norwegian Register of Business Enterprises	Expected on or about 21 December 2021
Delivery of the Offer Shares.....	Expected on or about 22 December 2021
Listing and commencement of trading in the Offer Shares on the Oslo Stock Exchange	Expected on or about 22 December 2021

11.5 Subscription Price

The Subscription Price in the Rights Issue is NOK 1.72 per Offer Share.

The Subscription Price represents a discount of approximately 35% to the theoretical share price exclusive of the Subscription Rights (TERP) based on the volume-weighted average share price (VWAP) of the Company's shares on the Oslo Stock Exchange of NOK 3.7424 on 24 November 2021.

11.6 Subscription Period

The Subscription Period will commence at 09:00 hours (CET) on 30 November 2021 and end at 16:30 hours (CET) on 14 December 2021. The Subscription Period may not be shortened, but the Board of Directors may extend the Subscription Period if this is required by law due to the publication of a supplement to the Prospectus. Subscription of Offer Shares shall be made on a separate subscription form.

11.7 Record Date for Existing Shareholders

Existing Shareholders who are registered in the Company's shareholder register in the VPS as of the Record Date (29 November 2021) will receive Subscription Rights.

Provided that the delivery of traded Shares was made with ordinary T+2 settlement in the VPS, Shares that were acquired until and including 25 November 2021 will give the right to receive Subscription Rights, whereas Shares that were acquired from and including 26 November 2021 will not give the right to receive Subscription Rights.

11.8 Subscription Rights

Existing Shareholders will be granted tradable Subscription Rights giving a preferential right to subscribe for, and be allocated, Offer Shares in the Rights Issue. Each Existing Shareholder will be granted 1.175114 Subscription Rights for each existing Share registered as held by such Existing Shareholder on the Record Date, rounded down to the nearest whole Subscription Right. Each Subscription Right will, subject to applicable securities laws, give the right to subscribe for, and be allocated, one Offer Share in the Rights Issue.

The Subscription Rights will be credited to and registered on each Existing Shareholder's VPS account on or about 30 November 2021 under ISIN NO0011147696. The Subscription Rights will be distributed free of charge to Existing Shareholders.

The Subscription Rights, including acquired Subscription Rights, must be used to subscribe for Offer Shares before the end of the Subscription Period (i.e. 14 December 2021 at 16:30 hours (CET)) or sold before 10 December 2021 at 16:30 hours (CET). Subscription Rights that are not sold before 10 December 2021 at 16:30 hours (CET) or exercised before 14 December 2021 at 16:30 hours (CET) will have no value and will lapse without compensation to the holder. Holders of Subscription Rights (whether granted or acquired) should note that subscriptions for Offer Shares must be made in accordance with the procedures set out in this Securities Note and that the acquisition of Subscription Rights does not in itself constitute a subscription for Offer Shares.

Subscription Rights of Existing Shareholders resident in jurisdictions where the Securities Note may not be distributed and/or with legislation that, according to the Company's assessment, prohibits or otherwise restricts subscription for Offer Shares and Existing Shareholders located in the United States who the Company does not reasonably believe to be a QIB (the "**Ineligible Shareholders**") will initially be credited to such Ineligible Shareholders' VPS accounts. Such crediting specifically does not constitute an offer to Ineligible Shareholders. The Company will instruct the Managers to, as far as possible, withdraw the Subscription Rights from such Ineligible Shareholders' VPS accounts, and may sell them in the period from and including 09:00 hours (CET) on 30 November 2021 to 16:30 hours (CET) on 10 December 2021 for the account and risk of such Ineligible Shareholders, unless the relevant Subscription Rights are held through a financial intermediary. See Section 11.12 "Financial intermediaries" below for a description of the procedures applicable to Subscription Rights held by Ineligible Shareholders through financial intermediaries.

The Managers will use commercially reasonable efforts to procure that the Subscription Rights withdrawn from the VPS accounts of Ineligible Shareholders (and that are not held through financial intermediaries) are sold on behalf of, and for the benefit of, such Ineligible Shareholders during the above period, provided that (i) the Managers are able to sell the Subscription Rights at a price at least equal to the anticipated costs related to the sale of such Subscription Rights, and (ii) the relevant Ineligible Shareholder has not by 16:30 hours (CET) on 6 December 2021 documented to the Company through one of the Managers the right to receive the Subscription Rights withdrawn from its VPS account, in which case the Managers shall re-credit the withdrawn Subscription Rights to the VPS account of the relevant Ineligible Shareholder. The proceeds from the sale of the Subscription Rights (if any), after deduction of customary sales expenses, will be credited to the Ineligible Shareholder's bank account registered in the VPS for payment of dividends, provided that the net proceeds attributable to such Ineligible Shareholder amount to or exceed NOK 200. If an Ineligible Shareholder does not have a bank account registered in the VPS, the Ineligible Shareholder must contact one of the Managers to claim the proceeds. If the net proceeds attributable to an Ineligible Shareholder are less than NOK 200, such amount will be retained for the benefit of the Company. There can be no assurance that the Managers will be able to withdraw and/or sell the Subscription Rights at a profit or at all. Other than as explicitly stated above, neither the Company nor the Managers will conduct any sale of Subscription Rights not sold before 16:30 hours (CET) on 10 December 2021 or utilized before the end of the Subscription Period.

11.9 Trading in Subscription Rights

The Subscription Rights will be tradable and listed on the Oslo Stock Exchange with ticker code "TRVXT" from and including 09:00 hours (CET) on 30 November 2021 to 16:30 hours (CET) on 10 December 2021.

The Subscription Rights will only be tradable during part of the Subscription Period.

Persons intending to trade in Subscription Rights should be aware that the trading in, and exercise of, Subscription Rights by holders who are located in jurisdictions outside Norway may be restricted or prohibited by applicable securities laws. See Section 12 "Selling and Transfer Restrictions" for a description of such restrictions and prohibitions.

11.10 Subscription procedures

Subscriptions for Offer Shares must be made by submitting a correctly completed subscription form included in Appendix A "Subscription form for the Rights Issue" (the "**Subscription Form**") to the Managers during the Subscription Period, or may, for Norwegian residents with a Norwegian personal identification number (Nw.: *fødselsnummer*), be made online as further described below.

Subscriptions for Offer Shares by subscribers who are not Existing Shareholders must also be made on a Subscription Form in the form included in Appendix A "Subscription form for the Rights Issue".

Correctly completed Subscription Forms must be received by one of the Managers at the following address or email address, or in the case of online subscriptions be registered, by 16:30 hours (CET) on 14 December 2021:

Carnegie AS	DNB Markets, Registrar Department
Fjordalléen 16	Dronning Eufemias gate 30
P.O. Box 684 Sentrum	P.O. Box 1600 Sentrum
N-0106 Oslo	N-0021 Oslo
Norway	Norway
Tel: +47 47 22 00 93 60	Tel: +47 23 26 80 20
E-mail: subscriptions@carnegie.no	E-mail: retail@dnb.no

Subscribers who are Norwegian residents with a Norwegian personal identification number (Nw.: *fødselsnummer*) are encouraged to subscribe for Offer Shares through the VPS online subscription system (or by following the link on www.carnegie.no/ongoing-prospectuses-and-offerings/ or www.dnb.no/emisjoner, which will redirect the subscriber to the VPS online subscription system). The VPS online subscription system is only available for individual persons and is not available for legal entities and legal entities must thus submit a Subscription Form in order to subscribe for Offer Shares.

None of the Company or the Managers may be held responsible for postal delays, unavailable internet lines or servers or other logistical or technical problems that may result in subscriptions not being received in time or at all by the Managers. Subscription Forms received after the end of the Subscription Period and/or incomplete or incorrect Subscription Forms and any subscription that may be unlawful may be disregarded at the sole discretion of the Company and/or the Managers without notice to the subscriber.

Subscriptions are binding and irrevocable, and cannot be withdrawn, cancelled or modified by the subscriber after having been received by one of the Managers or, in the case of subscriptions through the VPS online subscription system, upon registration of the subscription. The subscriber is responsible for the correctness of the information filled into the Subscription Form or, in the case of subscriptions through the VPS online subscription system, the online subscription registration. By signing and submitting a Subscription Form, or by registration of a subscription in the VPS online subscription system, the subscribers confirm and warrant that they have read this Securities Note and are eligible to subscribe for Offer Shares under the terms set forth herein.

There is no minimum subscription amount for which subscriptions in the Rights Issue must be made. Over-subscription (i.e. subscription for more Offer Shares than the number of Subscription Rights held by the subscriber) and subscription without Subscription Rights is permitted. However, in each case, there can be no assurance that Offer Shares will be allocated for such subscriptions.

Multiple subscriptions (i.e. subscriptions on more than one Subscription Form) are allowed. Please note, however, that two separate Subscription Forms submitted by the same subscriber with the same number of Offer Shares subscribed for on both Subscription Forms will only be counted once, unless otherwise is explicitly stated in one of the Subscription Forms. In the case of multiple subscriptions through the VPS online subscription system or subscriptions made both on a Subscription Form and through the VPS online subscription system, all subscriptions will be counted.

All subscriptions in the Rights Issue will be treated in the same manner regardless of whether the subscription is made by delivery of a Subscription Form to one of the Managers or through the VPS online subscription system.

11.11 Mandatory Anti-Money Laundering Procedures

The Rights Issue is subject to the Norwegian Money Laundering Act of 1 June 2018 No. 23 and the Norwegian Money Laundering Regulations of 14 September 2018 No. 1324 (collectively, the "**Anti-Money Laundering Legislation**").

Subscribers who are not registered as existing customers of the Managers must verify their identity to the Managers in accordance with the requirements of the Anti-Money Laundering Legislation, unless an exemption is available. Subscribers who have designated an existing Norwegian bank account and an existing VPS account on the Subscription Form are exempted, unless verification of identity is requested by the Managers. Subscribers who have not completed the required verification of identity prior to the expiry of the Subscription Period will not be allocated Offer Shares.

Furthermore, participation in the Rights Issue is conditional upon the subscriber holding a VPS account. The VPS account number must be stated in the Subscription Form. VPS accounts can be established with authorized VPS registrars, who can be Norwegian banks, authorized securities brokers in Norway and Norwegian branches of credit institutions established within the EEA. However, non-Norwegian investors may use nominee VPS accounts registered in the name of a nominee. The nominee must be authorized by the Norwegian FSA. Establishment of a VPS account requires verification of identification to the VPS registrar in accordance with the Anti-Money Laundering Legislation.

11.12 Financial intermediaries

11.12.1 General

All persons or entities holding Shares or Subscription Rights through financial intermediaries (e.g. brokers, custodians and nominees) should read this Section 11.12 "Financial intermediaries". All questions concerning the timeliness, validity and form of instructions to a financial intermediary in relation to the exercise of Subscription Rights should be determined by the financial intermediary in accordance with its usual customer relations procedure or as it otherwise notifies each beneficial shareholder.

The Company is not liable for any action or failure to act by a financial intermediary through which Shares are held.

11.12.2 Subscription Rights

If an Existing Shareholder holds Shares registered through a financial intermediary on the Record Date, the financial intermediary will customarily give the Existing Shareholder details of the aggregate number of Subscription Rights to which it will be entitled. The relevant financial intermediary will customarily supply each Existing Shareholder with this information in accordance with its usual customer relations procedures. Existing Shareholders holding Shares through a financial intermediary should contact the financial intermediary if they have received no information with respect to the Rights Issue.

Subject to applicable law, Existing Shareholders holding Shares through a financial intermediary may instruct the financial intermediary to sell some or all of their Subscription Rights, or to purchase additional Subscription Rights on their behalf. See Section 12 "Selling and Transfer Restrictions" for a description of certain restrictions and prohibitions applicable to the sale and purchase of Subscription Rights in certain jurisdictions outside Norway.

Existing Shareholders who hold their Shares through a financial intermediary and who are Ineligible Shareholders will not be entitled to exercise their Subscription Rights but may, subject to applicable law, instruct their financial intermediary to sell their Subscription Rights transferred to the financial intermediary. As described in Section 11.8 "Subscription Rights", neither the Company nor the Managers will sell any Subscription Rights transferred to financial intermediaries.

11.12.3 Subscription Period and period for trading in Subscription Rights

The time by which notification of exercise instructions for subscription of Offer Shares must validly be given to a financial intermediary may be earlier than the expiry of the Subscription Period. The same applies for instructions pertaining to trading in Subscription Rights and the last day of trading in such rights (which accordingly will be a deadline earlier than 10 December 2021 at 16:30 hours (CET)). Such deadlines will depend on the financial intermediary. Existing Shareholders who hold their Shares through a financial intermediary should contact their financial intermediary if they are in any doubt with respect to deadlines.

11.12.4 Subscription

Any Existing Shareholder who is not an Ineligible Shareholder and who holds its Subscription Rights through a financial intermediary and wishes to exercise its Subscription Rights, should instruct its financial intermediary in accordance with the instructions received from such financial intermediary. The financial intermediary will be responsible for collecting exercise instructions from the Existing Shareholders and for informing the Managers of such exercise instructions.

A person or entity who has acquired Subscription Rights that are held through a financial intermediary should contact the relevant financial intermediary for instructions on how to exercise the Subscription Rights.

See Section 12 "Selling and Transfer Restrictions" below for a description of certain restrictions and prohibitions applicable to the exercise of Subscription Rights in certain jurisdictions.

11.12.5 Method of payments

Any Existing Shareholder who holds its Subscription Rights through a financial intermediary should pay the Subscription Price for the Offer Shares that are allocated to it in accordance with the instructions received from the financial intermediary. The financial intermediary must pay the Subscription Price in accordance with the instructions in this Securities Note. Payment by the financial intermediary for the Offer Shares must be made to the Managers no later than

the Payment Date (as defined below). Accordingly, financial intermediaries may require payment to be provided to them prior to the Payment Date.

11.13 Allocation of the Offer Shares

Allocation of the Offer Shares will take place on or about 15 December 2021 in accordance with the following criteria:

- (i) Allocation of Offer Shares to subscribers will be made in accordance with granted and acquired Subscription Rights which have been validly exercised during the Subscription Period. Each Subscription Right will give the right to subscribe for and be allocated one Offer Share in the Rights Issue.
- (ii) Any unallocated Offer Shares following the allocation under item (i) above shall be allocated to those Underwriters who have subscribed Offer Shares in the Subscription Period, limited upwards to their respective underwriting obligation.
- (iii) If not all Subscription Rights are validly exercised during the Subscription Period and there are remaining unallocated Offer Shares following the allocation to the Underwriters who have subscribed Offer Shares in the Subscription Period pursuant to items (i) and (ii) above, subscribers who have exercised their Subscription Rights and who have over-subscribed, will be allocated additional Offer Shares on a pro rata basis based on the number of Subscription Rights exercised by each such subscriber. To the extent that pro rata allocation is not possible, the Company will determine the allocation by the drawing of lots.
- (iv) Offer Shares not allocated pursuant to item (i) to (iii) above, will be allocated to subscribers not holding Subscription Rights. Allocation will be sought made on a pro rata basis based on their respective subscription amounts.
- (v) Any Offer Shares remaining after allocation pursuant to (i) and (iv) above, will be subscribed by, and allocated to, the Underwriters pursuant to, and in accordance with, the underwriting obligation of the respective Underwriters.

No fractional Offer Shares will be allocated. The Company reserves the right to round off, reject or reduce any subscription for Offer Shares not covered by Subscription Rights (i.e. over-subscription or subscriptions made without Subscription Rights) and will only allocate such Offer Shares to the extent that Offer Shares are available to cover over-subscription based on Subscription Rights or subscriptions made without Subscription Rights.

Allocation of fewer Offer Shares than subscribed for by a subscriber will not impact on the subscriber's obligation to pay for the number of Offer Shares allocated.

Any Offer Shares that are unsubscribed by the end of the Subscription Period, will be subscribed by the Underwriters in accordance with the Underwriting Agreement, see Section 11.23 "The Underwriting".

The result of the Rights Issue is expected to be published on or about 15 December 2021 in the form of a stock exchange notification from the Company through the Oslo Stock Exchange information system. Notifications of allocated Offer Shares and the corresponding subscription amount to be paid by each subscriber are expected to be distributed in a letter from VPS on or about 15 December 2021. Subscribers having access to investor services through their VPS account manager will be able to check the number of Offer Shares allocated to them from 12:00 hours (CET) on 15 December 2021. Subscribers who do not have access to investor services through their VPS account manager may contact one of the Managers on telephone number +47 47 22 00 93 60 or +47 23 26 80 20 from 12:00 hours (CET) on 15 December 2021 to obtain information about the number of Offer Shares allocated to them.

11.14 Payment for the Offer Shares

The payment for Offer Shares allocated to a subscriber falls due on 17 December 2021 (the "**Payment Date**"). Payment must be made in accordance with the requirements set out in Sections 11.14.1 "Subscribers who have a Norwegian bank account" or 11.14.2 "Subscribers who do not have a Norwegian bank account".

11.14.1 Subscribers who have a Norwegian bank account

Subscribers who have a Norwegian bank account must, and will by signing the Subscription Form or by the online subscription registration for subscriptions through the VPS online subscription system, provide the Managers with a one-time irrevocable authorization to debit a specified Norwegian bank account for the amount payable for the Offer Shares which are allocated to the subscriber.

The specified bank account is expected to be debited on or after the Payment Date. The Managers are only authorized to debit such account once, but reserves the right to make up to three debit attempts, and the authorization will be valid for up to seven working days after the Payment Date.

The subscriber furthermore authorizes the Managers to obtain confirmation from the subscriber's bank that the subscriber has the right to dispose over the specified account and that there are sufficient funds in the account to cover the payment.

If there are insufficient funds in a subscriber's bank account or if it for other reasons is impossible to debit such bank account when a debit attempt is made pursuant to the authorization from the subscriber, the subscriber's obligation to pay for the Offer Shares will be deemed overdue.

Payment by direct debiting is a service that banks in Norway provide in cooperation. In the relationship between the subscriber and the subscriber's bank, the standard terms and conditions for "Payment by Direct Debiting – Securities Trading", which are set out on page 2 of the Subscription Form, will apply.

11.14.2 Subscribers who do not have a Norwegian bank account

Subscribers who do not have a Norwegian bank account must ensure that payment with cleared funds for the Offer Shares allocated to them is made on or before the Payment Date.

Prior to any such payment being made, the subscriber must contact one of the Managers on telephone number +47 22 00 93 60 or +47 23 26 80 20 for further details and instructions.

11.14.3 Overdue payments

Overdue payments will be charged with interest at the applicable rate from time to time under the Norwegian Act on Interest on Overdue Payment of 17 December 1976 No. 100, currently 8.00% per annum as of the date of this Securities Note. If a subscriber fails to comply with the terms of payment, the Offer Shares will, subject to the restrictions in the Norwegian Public Companies Act, not be delivered to such subscriber. The Managers, on behalf of the Company, reserve the right, at the risk and cost of the subscriber, at any time, to cancel the subscription and to re-allocate or otherwise dispose of allocated Offer Shares for which payment is overdue, or, if payment has not been received by the third day after the Payment Date, without further notice sell, assume ownership to or otherwise dispose of the allocated Offer Shares on such terms and in such manner as the Managers may decide in accordance with Norwegian law. The subscriber will remain liable for payment of the subscription amount, together with any interest, costs, charges and expenses accrued and the Managers, on behalf of the Company, may enforce payment for any such amount outstanding in accordance with Norwegian law.

The Company and the Managers further reserve the right (but have no obligation) to have the Managers advance the subscription amount on behalf of subscribers who have not paid for the Offer Shares allocated to them within the Payment Date. The non-paying subscribers will remain fully liable for the subscription amount payable for the Offer Shares allocated to them, irrespective of such payment by the Manager.

11.15 Delivery of the Offer Shares

Subject to timely payment of the entire subscription amount in the Rights Issue, the Company expects that the share capital increase pertaining to the Rights Issue will be registered with the Norwegian Register of Business Enterprises on or about 21 December 2021 and that the Offer Shares will be delivered to the VPS accounts of the subscribers to whom they are allocated on or about the next day. The final deadline for registration of the share capital increase pertaining to the Rights Issue with the Norwegian Register of Business Enterprises, and hence for the subsequent delivery of the Offer Shares, is, pursuant to the Norwegian Public Companies Act, three months from the expiry of the Subscription Period (i.e. three months from 14 December 2021).

11.16 Listing of the Offer Shares

The Shares are listed on the Oslo Stock Exchange under ISIN NO 0010689326 and ticker code "TRVX".

The Offer Shares will be listed on the Oslo Stock Exchange as soon as the share capital increase pertaining to the Rights Issue has been registered with the Norwegian Register of Business Enterprises and the Offer Shares have been registered in the VPS. The listing is expected to take place on or about 22 December 2021.

The Offer Shares may not be transferred or traded before they are fully paid, the share capital increase pertaining to the Rights Issue has been registered with the Norwegian Register of Business Enterprises, and the Offer Shares have been registered in the VPS.

11.17 The rights conferred by the Offer Shares

The Offer Shares issued in the Rights Issue will be ordinary Shares in the Company each having a nominal value of NOK 0.10. The Offer Shares will be issued electronically in registered form in accordance with the Norwegian Public Companies Act.

The Offer Shares will rank *pari passu* in all respects with the existing Shares and will carry full shareholder rights in the Company from the time of registration of the share capital increase pertaining to the Rights Issue with the Norwegian Register of Business Enterprises. The Offer Shares will be eligible for any dividends that the Company may declare after such registration. All Shares, including the Offer Shares, will have voting rights and other rights and obligations which are standard under the Norwegian Public Companies Act, and are governed by Norwegian law. See Section 8.2 "The Shares" for a more detailed description of the Shares and Section 8.3 "Certain aspects of Norwegian corporate law" for a more detailed description of certain aspects of Norwegian corporate law.

11.18 NCI code and LEI number

In order to participate in the Rights Issue, subscribers will need a global identification code. Physical persons will need a so-called National Client Identifier ("**NCI**") and legal entities will need a so-called Legal Entity Identifier ("**LEI**").

For physical persons with only a Norwegian citizenship, the NCI code is the 11 digit personal ID (Nw.: *fødselsnummer*). If the person in question has multiple citizenships or another citizenship than Norwegian, another relevant NCI code can be used. Subscribers are encouraged to contact their bank for further information.

LEI is a mandatory number for all companies investing in the financial market from January 2018. A LEI is a 20-character identifier that identifies distinct legal entities that engage in financial transactions. The Global Legal Identifier Foundation ("**GLEIF**") is not directly issuing LEIs, but instead it delegates this responsibility to Local Operating Units ("**LOUs**").

Norwegian companies can apply for a LEI number through the website <https://no.nordlei.org/>. The application can be submitted through an online form and signed electronically with BankID. It normally takes one to two working days to process the application.

Non-Norwegian companies can find a complete list of LOUs on the website <https://www.gleif.org/en/about-lei/get-an-lei-find-lei-issuing-organizations>.

11.19 VPS registration

The Subscription Rights will be registered in the VPS under ISIN NO 0011147696. The Offer Shares will be registered in the VPS with the same ISIN as the existing Shares, i.e. ISIN NO 0010689326.

The Company's registrar of shareholders in the VPS is administrated by Nordea Bank Norge ASA, Securities Services – Issuer Services with address Middelthuns gate 17, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway (the "**VPS Registrar**").

11.20 Dilution

The following table shows a comparison of participation in the Company's share capital and voting rights for existing shareholders before and after the Rights Issue, with the assumption that existing shareholders do not subscribe for Offer Shares and assuming that all the Offer Shares are issued:

	<u>Prior to the Rights Issue</u>	<u>Subsequent to the Rights Issue</u>
Total number of Shares each with a par value of NOK 0.10	86,582,405	188,326,591
% dilution		54%

The Company's total assets (non-current assets and current assets taken together) and liabilities (non-current liabilities and current liabilities taken together) as at 30 September 2021 were NOK 442,588 thousand and NOK 144,353 thousand, respectively, which translates to approximately NOK 3.44 in net asset value per Share at that date. The Subscription Price is NOK 1.72.

11.21 Timeliness, validity, form and eligibility of subscriptions

All questions concerning the timeliness, validity, form and eligibility of any subscription for Offer Shares will be determined by the Board of Directors, whose determination will be final and binding. The Board of Directors, or the Managers upon being authorized by the Board of Directors, may in their sole discretion waive any defect or irregularity in the Subscription Forms, permit such defect or irregularity to be corrected within such time as the Board of Directors or the Managers may determine, or reject the purported subscription of any Offer Shares. It cannot be expected that Subscription Forms will be deemed to have been received or accepted until all irregularities have been cured or waived within such time as the Board of Directors or the Managers shall determine. Neither the Board of Directors, the Company or the Managers will be under any duty to give notification of any defect or irregularity in connection with the submission of a Subscription Form or assume any liability for failure to give such notification. Further, neither the Board of Directors, the Company or the Managers are liable for any action or failure to act by a financial intermediary through whom any Existing Shareholder holds his Shares or by the Managers in connection with any subscriptions or purported subscriptions.

11.22 Share capital following the Rights issue

Upon registration of the share capital increase pertaining to the Offer Shares, the Company's share capital will be increased with NOK 10,174,418.60, and will be NOK 18,832,659.1 divided into 188,326,591 Shares, each with a nominal value of NOK 0.10.

11.23 The Underwriting

The Company and the Underwriters have entered into the Underwriting Agreement dated 3 November 2021, pursuant to which the Underwriters have undertaken, severally and not jointly, to underwrite an aggregate amount of NOK 166,915,000 in the Rights Issue (the "**Total Underwriting Obligation**"). The Underwriters have, limited to their respective underwritten amounts as set out in the table below, undertaken to subscribe and pay for the Offer Shares not subscribed for during the Subscription Period on or prior to the Payment Date.

The table below shows the subscription amount each Underwriter has undertaken to underwrite.

Name	Address	Underwritten amount (NOK)	% (approximately)
Modelio Equity AB.....	Ingmar Bergmans gata 2, 1114 34 Stockholm, Sweden	60,000,000	34.3%
Sundt AS.....	Dronningen 1, 0287 Oslo, Norway	22,500,000	12.9%
Wilhelm Risberg	Narvavägen 21, 11460 Stockholm, Sweden	20,500,000	11.7%
Fredrik Lundgren	Torgerdsvägen 4, 182 67 Djursholm, Sweden	20,500,000	11.7%
Nyenburgh Holding B.V.	Beursplein 5, 1012 JW Amsterdam, The Netherlands	19,415,000	11.1%
MP Pensjon	Lakkegata 23, 0187 Oslo, Norway	10,000,000	5.7 %
Jakob Ryer.....	Heimdalsvägen 1, 182 63 Djursholm, Sweden	5,000,000	2.9%
Myacom Investment AB.....	Torstenssonsgatan 3, 462 36 Vänersborg, Sweden	4,000,000	2.3%
Formue Nord Markedsneutral A/S .	Østre Alle 102, 9000 Aalborg, Denmark	4,000,000	2.3%
Karkas Capital AB.....	Hangövägen 29, 115 41 Stockholm, Sweden	1,000,000	0.6%
Total		166,915,000	95.4%

In addition to the Underwriters in the table above, AP4 (The Fourth Swedish National Pension Fund) has indicated a pro rata subscription in the Rights Issue, bringing the total underwritten and pre-subscribed amount to approximately NOK 175,000,000.

The Underwriters' obligations to subscribe and pay for the Offer Shares allocated to them in accordance with the Underwriting Agreement are conditional upon the following conditions: (i) the Underwriters having underwritten the Total Underwriting Obligation, (ii) the extraordinary general meeting of the Company validly having approved the Rights Issue and (iii) the Company having published a prospectus in relation to the Rights Issue approved by the Norwegian FSA. All of the conditions have been fulfilled at the time of publication of this Securities Note.

The Company may terminate the Underwriting Agreement in its sole discretion at any time prior to the registration of the share capital increase pertaining to the Rights Issue with the Norwegian Register of Business Enterprises. Prior to that date, the Underwriters may terminate the Underwriting Agreement in the event that the Company is in material

breach of the Underwriting Agreement. The Underwriters' obligations expire in the event that they have not been notified of any allotment under the Underwriting Agreement within 15 January 2022. In such event, the Rights Issue will be withdrawn unless it is fully subscribed. See Section 11.3 "Conditions for completion of the Rights Issue" for a description of the consequences of a withdrawal of the Rights Issue.

Pursuant to the Underwriting Agreement, each Underwriter will upon completion of the Rights Issue receive an underwriting fee of 8% of its respective underwritten amount.

11.24 Net proceeds and expenses related to the Rights Issue

The Managers will receive a success-based fee and commission as a per cent of the gross proceeds of the Rights Issue for their services rendered in connection therewith. Each Underwriter shall receive from the Company an underwriting commission equal to 8% of the amount of the relevant Underwriter's underwriting obligation. The total costs and expenses of, and incidental to, the Rights Issue are estimated to amount to approximately NOK 25 million. No expenses or taxes will be charged by the Company or the Managers to the subscribers in the Rights Issue.

Total net proceeds from the Rights Issue are estimated to amount to approximately NOK 150 million. For a description of the use of such proceeds, see Section 5 "Use of proceeds from the Rights Issue".

11.25 Interest of natural and legal persons involved in the Rights Issue

The Managers or their respective affiliates have provided from time to time, and may provide in the future, investment and commercial banking services to the Company and its affiliates in the ordinary course of business, for which they may have received and may continue to receive customary fees and commissions. The Managers, their respective employees and any affiliates may currently own existing Shares in the Company. Further, in connection with the Rights Issue, the Managers, their respective employees and any affiliates acting as an investor for its own account may receive Subscription Rights (if they are Existing Shareholders) and may exercise its right to take up such Subscription Rights and acquire Offer Shares, and, in that capacity, may retain, purchase or sell Subscription Rights or Offer Shares and any other securities of the Company or other investments for its own account and may offer or sell such securities (or other investments) otherwise than in connection with the Rights Issue. The Managers do not intend to disclose the extent of any such investments or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

Further, the Managers and the Underwriters will receive fees in connection with the Rights Issue, and, as such, have an interest in the Rights Issue. See Section 11.24 "Net proceeds and expenses related to the Rights Issue", for information on the fees to the Managers and the Underwriters.

11.26 Participation of major Existing Shareholders and members of the Company's Management, supervisory and administrative bodies in the Rights issue

To the Company's knowledge, the following members of the Board of Directors and Management intend to subscribe for Offer Shares in the Rights Issue:

Name	Position	Amount
Erik Digman Wiklund ¹	Chief Executive Officer	NOK 200,000
Øystein Soug ²	Special Advisor and interim Chief Financial Officer	NOK 200,000
Victor Levitsky	Chief Scientific Officer	NOK 20,212
Lone Ottesen	Chief Development Officer	NOK 100,000
Ola Melin	Head of Manufacturing	NOK 40,000
Diane Mellett.....	Board member	NOK 89,234
Robert Burns	Board member	NOK 120,000
Eva-Lotta Allan.....	Board member	NOK 34,400
Sonia Quaratino	Board member	NOK 17,200

1 Intend to subscribe for shares through Digman AS.

2 Intend to subscribe for shares through Abakus invest AS.

Further, certain Existing Shareholders have made underwriting commitments pursuant to the Underwriting Agreement (see Section 11.23 "The Underwriting" above).

Other than as set out above, the Company is not aware of whether any major shareholders of the Company or members of the Company's management, supervisory or administrative bodies intend to subscribe for Offer Shares in the Rights Issue, or whether any person intends to subscribe for more than 5% of the Rights Issue.

11.27 Publication of information relating to the Rights Issue

The Company will use the Oslo Stock Exchange information system to publish information relating to the Rights Issue.

11.28 Product Governance

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (MiFID II); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the MiFID II Product Governance Requirements), and disclaiming all and any liability, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the Target Market Assessment).

Notwithstanding the Target Market Assessment, distributors should note that (i) the price of the Shares may decline and investors could lose all or part of their investment, (ii) the Shares offer no guaranteed income and no capital protection and (iii) an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. Each distributor is responsible for undertaking its own Target Market Assessment in respect of the Shares and determining appropriate distribution channels.

The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Managers will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares.

11.29 Governing law and jurisdiction

This Securities Note, the Subscription Form and the terms and conditions of the Rights Issue shall be governed by, and construed in accordance with, and the Offer Shares and the Subscription Rights will be issued pursuant to, Norwegian law. Any dispute arising out of, or in connection with, the Subscription Forms or the Rights Issue shall be subject to the exclusive jurisdiction of the courts of Norway, with Oslo District Court as legal venue.

11.30 Advisors in the Rights Issue

Carnegie AS (Aker Brygge, Fjordalléen 16, N-0250 Oslo, Norway) and DNB Markets, a part of DNB Bank ASA, (Dronning Eufemias gate 30, N-0191 Oslo, Norway) acts as managers in the Rights Issue and Advokatfirmaet Thommessen AS (Ruseløkkveien 38, N-0251 Oslo, Norway) acts as Norwegian legal advisor to the Company in the Rights Issue.

12 SELLING AND TRANSFER RESTRICTIONS

This Securities Note does not constitute an offer or grant of, or an invitation to purchase any of, the Subscription Rights or the Offer Shares in any jurisdiction in which such offer or sale would be unlawful. No one has taken any action that would permit a public offering of Subscription Rights or Offer Shares to occur outside of Norway. Accordingly, neither this Securities Note nor any advertisement or any other offering material may be distributed or published in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. The Company and the Managers require persons in possession of this Prospectus to inform themselves about and to observe any such restrictions. The Subscription Rights and Offer Shares are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under applicable securities laws and regulations. Investors should be aware that they may be required to bear the financial risks of this investment for an indefinite period of time. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

12.1 General

The grant of Subscription Rights and issue of Offer Shares upon exercise of Subscription Rights and the offer of unsubscribed Offer Shares to persons resident in, or who are citizens of countries other than Norway, may be affected by the laws of the relevant jurisdiction. Investors should consult with their professional advisors as to whether they require any governmental or other consents or need to observe any other formalities to enable them to exercise Subscription Rights or purchase Offer Shares.

The Subscription Rights and Offer Shares being granted and offered, respectively, in the Rights Issue have not been and will not be registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not and will not be offered, sold, exercised, pledged, resold, granted, delivered, allocated, taken up, transferred or delivered, directly or indirectly, within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act and in compliance with the applicable securities laws of any state or jurisdiction of the United States. Receipt of this Securities Note will not constitute an offer in those jurisdictions in which it would be illegal to make an offer and, in those circumstances, this Securities Note is for information only and should not be copied or redistributed. Except as otherwise disclosed in this Securities Note, if an investor receives a copy of this Securities Note in any territory other than Norway, such investor may not treat this Securities Note as constituting an invitation or offer to it, or a grant of, nor should the investor in any event deal in Subscription Rights and/or Offer Shares (as the case may be), unless, in the relevant jurisdiction, such an invitation, offer or grant could lawfully be made to that investor, or the Subscription Rights and/or Offer Shares could lawfully be dealt in without contravention of any unfulfilled registration or other legal requirements. Accordingly, if an investor receives a copy of this Securities Note, the investor should not distribute or send the same, or transfer the Subscription Rights and/or the Offer Shares to any person or in or into any jurisdiction where to do so would or might contravene local securities laws or regulations. If the investor forwards this Securities Note into any such territories (whether under a contractual or legal obligation or otherwise), the investor should direct the recipient's attention to the contents of this Section 12 "Selling and Transfer Restrictions".

Except as otherwise noted in this Securities Note and subject to certain exceptions: (i) the Subscription Rights and Offer Shares being granted and offered, respectively, in the Rights Issue may not be offered, sold, resold, transferred or delivered, directly or indirectly, in or into, any jurisdiction in which it would not be permissible to grant the Subscription Rights or offer the Offer Shares, as applicable; (ii) this Securities Note may not be sent to any person in any jurisdiction in which it would not be permissible to offer the Offer Shares; and (iii) the crediting of Subscription Rights to an account of an holder or other person who is a resident of any jurisdiction in which it would not be permissible to offer the Offer Shares does not constitute an offer to such persons of the Offer Shares. Holders of Subscription Rights who are resident in any jurisdiction in which it would not be permissible to offer the Offer Shares may not exercise Subscription Rights.

If an investor exercises Subscription Rights to subscribe for Offer Shares, or purchases Offer Shares, either from the Company directly or from the Underwriters, unless the Company in its sole discretion determines otherwise on a case-by-case basis, that investor will be deemed to have made or, in some cases, be required to make, the following representations and warranties to the Company and any person acting on the Company's or its behalf:

- (a) the investor is not located or residing in a jurisdiction in which it would not be permissible to grant the Subscription Rights or offer the Subscription Rights and/or Offer Shares;
- (b) the investor is not a person to which the Rights Issue cannot be unlawfully made;

- (c) the investor is not acting, and has not acted, for the account or benefit of an a person to which the Rights Issue cannot be unlawfully made;
- (d) the investor is either a "qualified institutional buyer" as defined in Rule 144A under the U.S. Securities Act (a "QIB"), or acquiring the Offer Shares or Subscription Rights in an "offshore transaction" outside the United States within the meaning of, and pursuant to, Regulation S;
- (e) the investor understands that the Subscription Rights and the Offer Shares have not been and will not be registered under the U.S. Securities Act and may not be offered, sold, pledged, resold, granted, delivered, allocated, taken up or otherwise transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act;
- (f) the investor acknowledges that the Company is not taking any action to permit a public offering of the Offer Shares (pursuant to the exercise of the Subscription Rights or otherwise) or the Subscription Rights in any jurisdiction other than Norway; and
- (g) the investor may lawfully be offered, take up, subscribe for and receive Subscription Rights and Offer Shares in the jurisdiction in which it resides or is currently located.

The Company, the Managers and their affiliates and others will rely upon the truth and accuracy of the above acknowledgements, agreements and representations, and agree that, if any of the acknowledgements, agreements or representations deemed to have been made by its purchase of Offer Shares or Subscription Rights or by its exercise of Subscription Rights to subscribe for Offer Shares is no longer accurate, it will promptly notify the Company and the Manager. Any provision of false information or subsequent breach of these representations and warranties may subject the investor to liability.

If a person is acting on behalf of a holder of Subscription Rights (including, without limitation, as a nominee, custodian or trustee), that person will be required to provide the foregoing representations and warranties to the Company with respect to the exercise of Subscription Rights on behalf of the holder. If such person cannot or is unable to provide the foregoing representations and warranties, the Company will not be bound to authorize the allocation of any of the Offer Shares upon exercise of Subscription Rights or otherwise to that person or the person on whose behalf the other is acting. Subject to the specific restrictions described below, if an investor (including, without limitation, its nominees and trustees) is located outside Norway and wishes to exercise or otherwise deal in Subscription Rights or Offer Shares or subscribe for Offer Shares, the investor must satisfy itself as to full observance of the applicable laws of any relevant territory including obtaining any requisite governmental or other consents, observing any other requisite formalities and paying any issue, transfer or other taxes due in such territories.

The information set out in this Section 12 "Selling and Transfer Restrictions" is intended as a general guide only. If the investor is in any doubt as to whether it is eligible to exercise its Subscription Rights and subscribe for the Offer Shares, or deal in the Subscription Rights and/or the Offer Shares such investor should consult its professional advisor without delay.

The Company reserves the right to reject any exercise (or revocation of such exercise) in the name of any person who provides an address in a jurisdiction in which the Rights Issue cannot be lawfully made, or who is unable to represent or warrant that such person is not located or residing in such jurisdiction. Furthermore, the Company reserves the right, with sole and absolute discretion, to treat as invalid any exercise or purported exercise of Subscription Rights which appears to have been executed, effected or dispatched in a manner that may involve a breach or violation of the laws or regulations of any jurisdiction or the terms and conditions for the Rights Issue as set out in this Securities Note.

Notwithstanding any other provision of this Securities Note, the Company reserves the right to permit a holder to exercise its Subscription Rights if the Company, in its absolute discretion, is satisfied that the transaction in question is exempt from or not subject to the laws or regulations giving rise to the restrictions in question. Applicable exemptions in certain jurisdictions are described further below. In any such case, the Company does not accept any liability for any actions that a holder takes or for any consequences that it may suffer as a result of the Company accepting the holder's exercise of Subscription Rights.

Neither the Company nor the Manager, nor any of their respective representatives, is making any representation to any offeree, subscriber or purchaser of Offer Shares regarding the legality of an investment in the Subscription Rights or the

Offer Shares by such offeree, subscriber or purchaser under the laws applicable to such offeree, subscriber or purchaser. Each investor should consult its own advisors before subscribing for Offer Shares.

A further description of certain restrictions in relation to the Subscription Rights and the Offer Shares in certain jurisdictions is set out below.

12.2 United States

The Subscription Rights and/or Offer Shares, as applicable, have not been and will not be registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction in the United States and may not be offered, sold, pledged or otherwise transferred in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Subscription Rights and the Offer Shares are being offered (i) within the United States only QIBs, as defined in Rule 144A of the U.S. Securities Act, pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act, in each case, in accordance with any applicable securities laws of any state or territory of the United States or any other jurisdiction. Prospective purchasers of the Offer Shares are hereby notified that sellers of the Offer Shares may be relying on the exemption from registration provisions of Section 5 of the U.S. Securities Act provided by Rule 144A.

Except as set out below under "Sales within the United States" (i) neither this Securities Note nor the crediting of Subscription Rights to a stock account constitutes or will constitute an offer or an invitation to apply for or an offer or an invitation to acquire any Offer Shares in the United States, and this Securities Note will not be sent to any Existing Shareholder with a registered address in the United States and (ii) exercising Subscription Rights or renunciations thereof sent from or post-marked in the United States will be deemed to be invalid and all persons acquiring Offer Shares and wishing to hold such Offer Shares in registered form must provide an address for registration of the Offer Shares, issued upon exercise thereof outside the United States.

Until the expiration of 40 days as from the later of (a) the commencement of the Rights Issue, and (b) the commencement of any offering by underwriters of new shares underlying unexercised preferential subscription rights, an offer, sale or transfer of the Offer Shares or preferential subscription rights within the United States by a dealer (whether or not participating in the Rights Issue) may violate the registration requirements of the U.S. Securities Act if such offer or sale is made otherwise than in accordance with Rule 144A under the U.S. Securities Act.

In making an investment decision with respect to the Subscription Rights or the Offer Shares, investors must rely on their own examination of the Company and the terms of the Rights Issue, including the merits and risks involved. The Subscription Rights and the Offer Shares have not been recommended, approved or disapproved by the U.S. Securities and Exchange Commission, any state securities commission in the United States or any other United States regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Subscription Rights and the Offer Shares or the accuracy or adequacy of this document. Any representation to the contrary is a criminal offense in the United States.

Sales within the United States

Notwithstanding the foregoing, the Offer Shares may be offered to and the Subscription Rights may be exercised by or on behalf of, persons in the United States reasonably believed to be QIBs, in offerings exempt from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act, provided such persons satisfy the Company that they are eligible to participate on such basis. Persons in the United States exercising Subscription Rights to acquire Offer Shares will be required to execute an investor letter in a form acceptable to the Company and the Managers.

Each person exercising Subscription Rights and each purchaser of Offer Shares, either from the Company directly or from the Underwriters, within the United States pursuant to an exemption from the registration requirements of the U.S. Securities Act, by accepting delivery of this Securities Note, will be deemed to have represented, warranted, agreed and acknowledged that:

- a) It is (i) a QIB and (iii) exercising such Subscription Rights or acquiring such Offer Shares for its own account or for the account QIB as to which it has full investment discretion, in each case for investment purposes, and not with a view to any distribution (within the meaning of the U.S. federal securities laws) of the Shares.

b) It understands that such Subscription Rights and Offer Shares are being offered for sale in a transaction not involving any public offering in the United States and the Subscription Rights and Offer Shares have not been and will not be registered under the U.S. Securities Act or any U.S. securities laws or with any securities regulatory authority of any state or other jurisdiction in the United States and may not be offered, sold, pledged or otherwise transferred except (i)(A) in accordance with Rule 144A to a person that it and any person acting on its behalf reasonably believe is a QIB purchasing for its own account or for the account of a QIB, (B) in an "offshore transaction" as defined in and in accordance with Rule 903 or Rule 904 of Regulation S under the U.S. Securities Act, (C) pursuant to an exemption from registration under the U.S. Securities Act provided by Rule 144 thereunder (if available), (D) pursuant to any other available exemption from registration under the U.S. Securities Act or (E) pursuant to an effective registration statement under the U.S. Securities Act, and (ii) in accordance with all applicable federal and state securities laws of the United States.

c) It understands that each of such Subscription Rights and Offer Shares (to the extent they are in certificated form), unless otherwise determined by the Company in accordance with applicable law, will bear a legend substantially to the following effect:

THIS SECURITY HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (A)(1) IN ACCORDANCE WITH RULE 144A UNDER THE U.S. SECURITIES ACT TO A PERSON THAT THE HOLDER AND ANY PERSON ACTING ON ITS BEHALF REASONABLY BELIEVE IS A QIB WITHIN THE MEANING OF RULE 144A PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QIB, (2) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT, (3) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE), (4) PURSUANT TO ANY OTHER AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT OR (5) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT, AND (B) IN ACCORDANCE WITH ALL APPLICABLE FEDERAL AND STATE SECURITIES LAWS OF THE UNITED STATES. NO REPRESENTATION CAN BE MADE AS TO THE AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 UNDER THE U.S. SECURITIES ACT FOR REALES OF THIS SECURITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE FOREGOING, THIS SECURITY MAY NOT BE DEPOSITED INTO ANY UNRESTRICTED DEPOSITARY RECEIPT FACILITY IN RESPECT OF SECURITIES ESTABLISHED OR MAINTAINED BY A DEPOSITARY BANK.

d) The Company, the Manager, and any selling agents and others will rely upon the truth and accuracy of the foregoing acknowledgements, representations and agreements. If it is exercising any Subscription Rights or acquiring any Offer Shares for the account of one or more QIBs, it represents that it has sole investment discretion with respect to each such account and that it has full power to make the foregoing acknowledgements, representations and agreements on behalf of each such account.

e) The Subscription Rights and the Offer Shares have not been offered to it by means of any "general solicitation" or "general advertising" as such terms are used in Regulation D under the U.S. Securities Act.

f) The Company shall not recognize any offer, sale, pledge or other transfer of the Subscription Rights or the Offer Shares made other than in compliance with the above-stated restrictions.

No representation has been, or will be, made by the Company or the Managers as to the availability of Rule 144 under the U.S. Securities Act or any other exemption under the U.S. Securities Act or any state securities laws for the re-offer, sale, pledge or transfer of the Offer Shares for so long as the Offer Shares are "restricted securities" within the meaning of Rule 144(a)(3) under the U.S. Securities Act.

Any person in the United States into whose possession this Securities Note comes should inform itself about and observe any applicable legal restrictions; any such person in the United States who is not a QIB is required to disregard this Securities Note. A person in the United States who is not a QIB is an Ineligible Shareholder (as defined in Section 11.8 "Subscription Rights"). The credit of Subscription Rights to an Ineligible Shareholder does not constitute an offer to such Ineligible Shareholders.

Prospective purchasers are hereby notified that sellers of the Offer Shares may be relying on the exemption from the provisions of Section 5 of the U.S. Securities Act provided by Rule 144A.

Sales outside the United States

Each person that at the time of exercise of Subscription Rights or purchase of Offer Shares, either from the Company directly or from the Underwriters, was outside the United States, by accepting delivery of this Securities Note, will be deemed to have represented, warranted, agreed and acknowledged that:

- a) It (i) is not within the United States; (ii) is not in any jurisdiction in which it is unlawful to make or accept an offer to acquire the Subscription Rights or the Offer Shares; (iii) is not exercising for the account of any person who is located in the United States, unless: (A) the instruction to exercise was received from a person outside the United States and (B) the person giving such instruction has confirmed that (x) it has the authority to give such instruction, and (y) either (a) has investment discretion over such account or (b) is an investment manager or investment company that is acquiring the Subscription Rights or the Offer Shares in an "offshore transaction" within the meaning of Regulation S under the U.S. Securities Act; and (iv) is not acquiring the Subscription Rights or the Offer Shares with a view to the offer, sale, resale, transfer, delivery or distribution, directly or indirectly, of any such Subscription Rights or Offer Shares into the United States.
- b) It understands that such Subscription Rights and Offer Shares have not been and will not be registered under the U.S. Securities Act or any U.S. securities laws or with any securities regulatory authority of any state or other jurisdiction in the United States and that it will not offer, sell, pledge or otherwise transfer such Subscription Rights or Offer Shares except (i) in accordance with Rule 144A under the U.S. Securities Act to a person it and any person acting on its behalf reasonably believe is a QIB purchasing for its own account or the account of a QIB or (ii) in an offshore transaction as defined in and in accordance with Rule 903 or Rule 904 of Regulation S under the U.S. Securities Act, in each case in accordance with any applicable securities laws of any State of the United States.
- c) It understands that such Offer Shares (to the extent they are in certificated form), unless otherwise determined by the Company in accordance with applicable law, will bear a legend to the following effect:

THIS SECURITY HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER, OR IN A TRANSACTION NOT SUBJECT TO, THE U.S. SECURITIES ACT.
- d) It is aware of the restrictions on the offer and sale of the Subscription Rights and Offer Shares pursuant to Regulation S described in this Securities Note.
- e) The Subscription Rights and the Offer Shares have not been offered to it by means of any "directed selling efforts" as defined in Regulation S.
- f) The Company, the Manager, any selling agents and others will rely upon the truth and accuracy of the foregoing acknowledgements, representations and agreements.
- g) The Company shall not recognize any offer, sale, pledge or other transfer of the Offer Shares made other than in compliance with the above restrictions.

The Company is not required to file periodic reports under Section 13 or 15 of the U.S. Exchange Act. For as long as any of the Offer Shares are "restricted securities" within the meaning of Rule 144(a)(3) under the U.S. Securities Act, and the Company is neither subject to Section 13 or 15(d) of the Exchange Act, nor exempt from reporting pursuant to Rule 12g3-2(b) under the Exchange Act, the Company will upon written request furnish to any holder or beneficial owner of the Offer Shares, or to any prospective purchaser designated by such holder, the information specified in, and meeting the requirements of, Rule 144A(d)(4) under the U.S. Securities Act.

12.3 United Kingdom

No Subscription Rights or Offer Shares have been offered or will be offered to the public in the United Kingdom, except that the Subscription Rights or Offer Shares may be offered in the United Kingdom at any time:

- a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;

- b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the Managers for any such offer; or
- c) in any other circumstances falling within Section 86 of the FSMA,

provided that no such offer of the Subscription Rights or Offer Shares shall require the Company or any Managers to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.

For the purposes of this provision, the expression an "offer to the public" in relation to the Offer Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares and the expression "UK Prospectus Regulation" means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

12.4 European Economic Area

In relation to each Relevant Member State, an offer to the public of any Offer Shares may not be made in that Relevant Member State, other than the offers contemplated by this Securities Note in Norway once this Securities Note has been approved by the Norwegian FSA and published in accordance with the EU Prospectus Regulation as implemented in Norway, except that an offer to the public of any Offer Shares in a Relevant Member State may be made at any time under the following exemptions under the EU Prospectus Regulation:

- a) to persons who are "qualified investors" within the meaning of Article 2(e) of the EU Prospectus Regulation;
- b) to fewer than 150, natural or legal persons (other than qualified investors as defined in the EU Prospectus Regulation) per Relevant Member State, with the prior written consent of the Managers for any such offer; or
- c) in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation,

provided that no such offer of Offer Shares shall result in a requirement for the Company or any Managers to publish a prospectus pursuant to Article 3 of the EU Prospectus Regulation or supplementary prospectus pursuant to Article 23 of the EU Prospectus Regulation.

For the purposes of this provision, the expression an "offer" in relation to any of the Offer Shares or Shares in any Relevant Member States means the communication in any form and by any means of sufficient information on the terms of the offer and any Offer Shares or Shares to be offered so as to enable an investor to decide to purchase or subscribe for such Offer Shares or Shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State.

Each person in a Relevant Member State who receives any communication in respect of, or who acquires any Offered Shares under, the Rights Issue contemplated hereby will be deemed to have represented, warranted and agreed to and with each of the Company and the Managers that it is a qualified investor within the meaning of Article 2(e) of the EU Prospectus Regulation.

The Company, the Managers and their respective affiliates and its and their respective directors, employees, agents, advisers, subsidiaries and others will rely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement.

12.5 Switzerland

This Securities Note is not being publicly distributed in Switzerland. Each copy of this Securities Note is addressed to a specifically named recipient and may not be passed on to third parties. The Subscription Rights or Offer Shares are not being offered to the public in or from Switzerland, and neither this Securities Note, nor any other offering material in relation to the Subscription Rights or Offer Shares may be distributed in connection with any such public offering.

12.6 Additional Jurisdictions

The Subscription Rights or Offer Shares may not be offered, sold, exercised, pledged, resold, granted, allocated, taken up, transferred or delivered, directly or indirectly, in or into, Canada, Japan, Australia, Hong Kong or any other jurisdiction in which it would not be permissible to offer the Subscription Rights or the Offer Shares.

13 DEFINITIONS AND GLOSSARY

In the Securities Note, the following defined terms have the following meanings:

Anti-Money Laundering Legislation	The Norwegian Money Laundering Act of 1 June 2018 No. 23 and the Norwegian Money Laundering Regulations of 14 September 2018 No. 1324.
Articles of Association	The Company's articles of association.
Board Members	The members of the Board of Directors.
Board of Directors.....	The board of directors of the Company.
Business Finland.....	The Finnish trade promotion organization and the Finnish Funding Agency for Technology and Innovation (TEKES) united as "Business Finland" in 2018.
CET	Central European Time.
Company.....	Targovax ASA.
EEA	The European Economic Area.
EMA.....	The European Medicines Agency.
EU Prospectus Regulation	Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC Text with EEA relevance
EUR	The lawful common currency of the EU member states who have adopted the Euro as their sole national currency.
Excess allowance.....	Any part of the calculated allowance one year exceeding the dividend distributed on the share.
Existing Shareholders.....	The shareholders of the Company as of 25 November 2021 (and being registered as such in the "VPS") as at the expiry of 29 November 2021, pursuant to the two days' settlement procedure of VPS.
FDA	The U.S. Food and Drug Administration.
Financial Information	The financial information incorporated by reference into the Registration Document as supplemented by the Supplemental Prospectus, comprising the Group's audited consolidated financial statements as of and for the year ended 31 December 2020 and the Group's unaudited interim consolidated financial statements as of and for the three and six months' periods ended 30 June 2021.
FSMA	The Financial Services and Markets Act 2000.
General Meeting	The general meeting of the shareholders in the Company.
GLEIF.....	The Global Legal Identifier Foundation.
HealthCap.....	HealthCap V L.P.
Ineligible Shareholders.....	Existing Shareholders resident in jurisdictions where the Securities Note may not be distributed and/or with legislation that, according to the Company's assessment, prohibits or otherwise restricts subscription for Offer Shares and Existing Shareholders located in the United States who the Company does not reasonably believe to be a QIB.
LEI	Legal Entity Identifier.
LOUs.....	Local Operating Units.
Management.....	The senior management team of the Company.
Managers	Carnegie AS and DNB Markets, a part of DNB Bank ASA.
MiFID II.....	EU Directive 2014/65/EU on markets in financial instruments, as amended.
MiFID II Product Governance Requirements.....	Means the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended; (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures.
NCI.....	National Client Identifier.
NOK.....	Norwegian Kroner, the lawful currency of Norway.
Non-Norwegian Corporate Shareholders.....	Shareholders who are limited liability companies (and certain other entities) not resident in Norway for tax purposes.
Non-Norwegian Personal Shareholder	Shareholders who are individuals not resident in Norway for tax purposes.
Nordea	Nordea Bank Norge ASA.
Norwegian Corporate Shareholders.....	Shareholders who are limited liability companies and certain similar corporate entities resident in Norway for tax purposes.
Norwegian FSA.....	The Financial Supervisory Authority of Norway (<i>Nw.: Finanstilsynet</i>).
Norwegian Personal Shareholders	Shareholders who are individuals resident in Norway for tax purposes.

Norwegian Public Limited Companies Act	The Norwegian Public Limited Companies Act of 13 June 1997 no. 45 (<i>Nw.: allmennaksjeloven</i>).
Norwegian Securities Trading Act.	The Norwegian Securities Trading Act of 29 June 2007 no. 75 (<i>Nw.: verdipapirhandelloven</i>).
ONCOS-102	Targovax's lead product candidate. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells.
Offer Shares	101,744,186 new shares in the Company, each with a par value of NOK 0.10, to be issued in connection with the Right Issue.
Order	The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended.
Oslo Stock Exchange	Oslo Børs ASA, or, as the context may require, Oslo Børs, a Norwegian regulated stock exchange operated by Oslo Børs ASA.
Payment Date	On or about 17 December 2021.
Prospectus.....	The prospectus prepared by the Company in connection with the Rights Issue and the listing of the Offer Shares, comprising this Securities Note and the Registration Document dated 29 November 2021 as approved by the Norwegian FSA on 29 November 2021.
QIBs	"Qualified institutional buyers" as defined in Rule 144A.
Record Date.....	The expiry of 29 November 2021, pursuant to the two days' settlement procedure of VPS.
Registration Document	The registration document dated 29 November 2021.
Regulation S	Regulation S under the U.S. Securities Act.
Relevant Member State	Each Member State of the European Economic Area which has implemented the EU Prospectus Regulation.
Relevant Persons	Persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Order or (ii) high net worth entities, and other persons to whom the Securities Note may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order.
Rights Issue.....	The offering of 101,744,186 Offer Shares at a Subscription Price of NOK 1.72 per Offer Share with Subscription Rights for Existing Shareholders, as further described in Section 11 "The terms of the Rights Issue".
RSUs.....	Restricted stock units.
Rule 144A.....	Rule 144A under the U.S. Securities Act.
Securities Note.....	This Securities Note dated 29 November 2021.
Share(s).....	Means the shares of the Company, each with a nominal value of NOK 0.10, or any one of them.
Subscription Form	The form for subscription of Offer Shares attached hereto in Appendix A.
Subscription Period	From 09:00 hours (CET) on 30 November 2021 and expire at 16:30 hours CET on 14 December 2021.
Subscription Price	Subscription rights that, subject to applicable law, provide preferential rights to subscribe for and to be allocated Offer Shares at the Subscription Price.
Subscription Rights	The subscription price for the Offer Shares, being NOK 1.72.
Target Market Assessment.....	The product approval process, which has determined that the shares each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II.
Targovax or Group.....	The Company and its consolidated subsidiaries.
Targovax Oy	Targovax Oy, a wholly owned subsidiary of the Company (previously named Oncos Therapeutics Oy).
Total Underwriting Obligation	The aggregate amount of NOK 166,915,000 which the Underwriters have undertaken, severally and not jointly, to underwrite in the Rights Issue pursuant to the Underwriting Agreement.
UK	United Kingdom.
Underwriters	Certain existing shareholders of the Company and new investors as listed in Section 11.23 "The Underwriting".
Underwriting Agreement.....	The underwriting agreement entered into between the Company and the Underwriters dated 3 November 2021.
U.S. or United States	The United States of America.
U.S. Exchange Act	The U.S. Securities Exchange Act of 1934, as amended.
U.S. Securities Act.....	The U.S. Securities Act of 1933, as amended.
USD or U.S. Dollar.....	United States Dollars, the lawful currency of the United States.
VPS	The Norwegian Central Securities Depository (<i>Nw.: Verdipapirsentralen</i>).
VPS Registrar.....	Nordea Bank Norge ASA, Securities Services – Issuer Services with address Middelthuns gate 17, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway.

APPENDIX A
SUBSCRIPTION FORM

General information: The terms and conditions of the rights issue (the "Rights Issue") of 101,744,186 new shares (the "Offer Shares") in Targovax ASA (the "Company") pursuant to a resolution by the Company's extraordinary general meeting held on 25 November 2021 are set out in the prospectus dated 29 November 2021 (comprising the Securities Note and the Registration Document, all dated 29 November 2021, the "Prospectus"). Terms defined in the Prospectus shall have the same meaning in this subscription form (the "Subscription Form"). The notice of, and the minutes from, the extraordinary general meeting held on 25 November 2021 (with appendices), the Company's articles of association and the annual accounts and directors' reports for the last two years are available at the Company's registered office at Vollsveien 19, N-1366 Lysaker, Norway.

Subscription procedure: The subscription period will commence at 09:00 hours (CET) on 30 November 2021 and expire at 16:30 hours CET on 14 December 2021 (the "Subscription Period"). The Subscription Period may be extended if required by law due to the publication of a supplemental prospectus. Correctly completed Subscription Forms must be received by one of the Managers no later than on 14 December at 16:30 hours (CET) at one of the following addresses: Carnegie AS: P.O. Box 684 Sentrum, N-0106 Oslo, Norway or DNB Markets, Registrar Department: Dronning Eufemias gate 30, P.O. Box 1600 Sentrum, N-0021 Oslo, Norway or email: subscriptions@carnegie.no or retail@dnb.no, or in case of online subscriptions be registered, no later than 16:30 hours (CET) on 14 December 2021. The subscriber is responsible for the correctness of the information included in the Subscription Form. Subscription Forms received after the end of the Subscription Period and/or incomplete or incorrect Subscription Forms and any subscription that may be unlawful may be disregarded at the sole discretion of the Company and/or the Managers without notice to the subscriber.

Subscribers who are Norwegian residents with a Norwegian personal identity number (Nw.: fødselsnummer) are encouraged to subscribe for Offer Shares through the VPS online subscription system (or by following the link on <https://www.carnegie.no/ongoing-prospectuses-and-offerings> or www.dnb.no/emisjoner which will redirect the subscriber to the VPS online subscription system). Subscriptions made through the VPS online subscription system must be duly registered before the expiry of the Subscription Period.

Neither the Company nor the Managers may be held responsible for postal delays, unavailable internet lines or servers or other logistical or technical problems that may result in subscriptions not being received in time or at all by the Managers. Subscriptions are binding and irrevocable, and cannot be withdrawn, cancelled or modified by the subscriber after being received by the Managers or, in the case of subscriptions through the VPS online subscription system, upon registration of the subscription. By

signing and submitting this Subscription Form, or registering a subscription through the VPS online subscription system, the subscriber confirms and warrants to have read the Prospectus and to be eligible to subscribe for Offer Shares under the terms set forth therein.

Subscription Price: The subscription price in the Rights Issue is NOK 1.72 per Offer Share (the "Subscription Price").

Subscription Rights: The shareholders of the Company as of 25 November 2021 (and being registered as such in the VPS at the expiry of 29 November 2021 pursuant to the two days' settlement procedure (the "Record Date")) (the "Existing Shareholders"), will be granted subscription rights (the "Subscription Rights") in the Rights Issue that, subject to applicable law, provide preferential right to subscribe for, and be allocated, Offer Shares at the Subscription Price. The Subscription Rights will be listed and tradable on the Oslo Stock Exchange from 09:00 hours (CET) on 30 November 2021 to 16:30 hours (CET) on 10 December 2021 under the ticker code "TRVXT". **The subscription rights will hence only be tradable during part of the Subscription Period.** Existing Shareholders will be granted 1.175114 Subscription Rights for each existing Share registered as held by such Existing Shareholder as of the Record Date, rounded down to the nearest whole Subscription Right. Subscription Rights acquired during the trading period for the Subscription Rights carry the same right to subscription as the Subscription Rights held by Existing Shareholders. Each Subscription Right will, subject to applicable securities laws, give the right to subscribe for, and be allocated, one Offer Share. Over-subscription (i.e. subscription for more Offer Shares than the number of Subscription Rights held by the subscriber) and subscription without Subscription Rights is permitted. However, in each case, there can be no assurance that Offer Shares will be allocated for such subscriptions. **Subscription Rights that are not used to subscribe for Offer Shares before the expiry of the Subscription Period (i.e. 14 December 2021 at 16:30 hours (CET)) or sold before 10 December 2021 at 16:30 hours (CET) will have no value and will lapse without compensation to the holder.**

Allocation of Offer Shares: The Offer Shares will be allocated to the subscribers based on the allocation criteria set out in the Prospectus. No fractional Offer Shares will be allocated. The Company reserves the right to round off, reject or reduce any subscription for Offer Shares not covered by Subscription Rights (i.e. over-subscription or subscriptions made without Subscription Rights) and will only allocate such Offer Shares to the extent that Offer Shares are available to cover over-subscription based on Subscription Rights or subscriptions made without Subscription Rights. Allocation of fewer Offer Shares than subscribed for by a subscriber will not impact on the subscriber's obligation to pay for the number of Offer Shares allocated. Notification of allocated Offer Shares and the corresponding subscription amount to be paid by each subscriber are expected to be distributed in a letter from the VPS on or about 15 December 2021. Subscribers having access to investor services through their VPS account manager will be able to check the number of Offer Shares allocated to them from 12:00 hours (CET) on 15 December 2021. Subscribers who do not have access to investor services through their VPS account manager may contact one of the Managers from 12:00 hours (CET) on 15 December 2021 to obtain information about the number of Offer Shares allocated to them.

Payment: The payment for Offer Shares allocated to a subscriber falls due on 17 December 2021 (the "Payment Date"). By signing this Subscription Form, subscribers having a Norwegian bank account provide the Managers with a one-time irrevocable authorisation to debit the bank account specified below for the subscription amount payable for the Offer Shares allocated to the subscriber. The Managers are only authorised to debit such account once, but reserves the right to make up to three debit attempts, and the authorisation will be valid for up to seven working days after the Payment Date. The subscriber furthermore authorises the Managers to obtain confirmation from the subscriber's bank that the subscriber has the right to dispose over the specified account and that there are sufficient funds in the account to cover the payment. If there are insufficient funds in a subscriber's bank account or if it for other reasons is impossible to debit such bank account when a debit attempt is made pursuant to the authorisation from the subscriber, the subscriber's obligation to pay for the Offer Shares will be deemed overdue. Subscribers who do not have a Norwegian bank account must ensure that payment with cleared funds for the Offer Shares allocated to them is made on or before the Payment Date. Prior to any such payment being made, the subscriber must contact the Managers on telephone number +47 22 00 93 60 or +47 23 26 80 20 for further details and instructions. Should any subscriber have insufficient funds on his or her account, should payment be delayed for any reason, if it is not possible to debit the account or if payments for any other reasons are not made when due, overdue interest will accrue and other terms will apply as set out under the heading "Overdue and missing payments" below.

PLEASE SEE PAGE 2 OF THIS SUBSCRIPTION FORM FOR OTHER PROVISIONS THAT ALSO APPLY TO THE SUBSCRIPTION

DETAILS OF THE SUBSCRIPTION

Subscriber's VPS account	Subscriber's LEI code (20 digits):	Number of Subscription Rights	Number of Offer Shares subscribed (incl. over-subscription)	(For broker: Consecutive no.)
SUBSCRIPTION RIGHTS' SECURITIES NUMBER: ISIN NO 0011147696			Subscription Price per Offer Share X NOK 1.72	Subscription amount to be paid = NOK _____

IRREVOCABLE AUTHORISATION TO DEBIT ACCOUNT (MUST BE COMPLETED BY SUBSCRIBERS WITH A NORWEGIAN BANK ACCOUNT)

Norwegian bank account to be debited for the payment for Offer Shares allocated (number of Offer Shares allocated x NOK 1.72).	<input type="text"/>
	(Norwegian bank account no.)

In accordance with the terms and conditions set out in the Prospectus and this Subscription Form, I/we hereby irrevocably subscribe for the number of Offer Shares specified above and grant the Managers authorisation to debit (by direct debiting or manually as described above) the specified bank account for the payment of the Offer Shares allocated to me/us. By signing this Subscription Form, subscribers subject to direct debiting accept the terms and conditions for "Payment by Direct Debiting – Securities Trading" set out on page 2 of this Subscription Form.

Place and date
Must be dated in the Subscription Period

Binding signature. The subscriber must have legal capacity. When signed on behalf of a company or pursuant to an authorisation, documentation in the form of a company certificate or power of attorney should be attached.

INFORMATION ON THE SUBSCRIBER

First name:	
Surname / company:	
Street address:	
Post code / district / country:	
Personal ID number / company registration number:	
Legal Entity Identifier ("LEI") / National Client Identifier ("NCI"):	
Nationality:	
E-mail address:	
Daytime telephone number:	

ADDITIONAL GUIDELINES FOR THE SUBSCRIBER

Regulatory Issues: In accordance with the Markets in Financial Instruments Directive (MiFID II) of the European Union, Norwegian law imposes requirements in relation to business investments. In this respect the Managers must categorise all new clients in one of three categories: eligible counterparties, professional and non-professional clients. All subscribers in the Rights Issue who are not existing clients of the Managers will be categorised as non-professional clients. Subscribers can by written request to the Managers ask to be categorised as a professional client if the subscriber fulfils the applicable requirements of the Norwegian Securities Trading Act. For further information about the categorisation, the subscriber may contact the Manager. **The subscriber represents that he/she/it is capable of evaluating the merits and risks of an investment decision to invest in the Company by subscribing for Offer Shares, and is able to bear the economic risk, and to withstand a complete loss, of an investment in the Offer Shares.**

The Managers will receive a consideration from the Company and will in conducting its work have to take into consideration the requirements of the Company and the interests of the investors subscribing under the Rights Issue and the rules regarding inducements pursuant to the requirements of the Norwegian MiFID II Regulations (implementing the European Directive for Markets in Financial Instruments (MiFID II)).

Selling and Transfer Restrictions: The attention of persons who wish to acquire Subscription Rights and/or subscribe for Offer Shares is drawn to Section 12 of the Securities Note "Selling and transfer restrictions". The making or acceptance of the Rights Issue to or by persons who have registered addresses outside Norway, or who are resident in, or citizens of, countries outside Norway, may be affected by the terms of the Rights Issue and the laws of the relevant jurisdiction. Those persons should read Section 12 of the Securities Note and consult their professional advisers as to whether they are eligible to acquire Subscription Rights and/or subscribe for Offer Shares or require any governmental or other consents or need to observe any other formalities to enable them to acquire Subscription Rights and/or subscribe for Offer Shares. It is the responsibility of any person outside Norway wishing to acquire Subscription Rights and/or subscribe for Offer Shares under the Rights Issue to satisfy himself/herself/itself as to the full observance of the terms and conditions of the Rights Issue and the laws of any relevant jurisdiction in connection therewith, including obtaining any governmental or other consent which may be required, the compliance with other necessary formalities and the payment of any issue, transfer or other taxes due in such territories. The Subscription Rights and the Offer Shares have not been registered and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), or under the securities law of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, delivered or transferred, directly or indirectly, within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States. There will be no public offer of the Subscription Rights and the Offer Shares in the United States. Notwithstanding the foregoing, the Offer Shares may be offered to and the Subscription Rights may be exercised by or on behalf of, persons in the United States reasonably believed to be "qualified institutional buyers" (QIBs) as defined by the U.S. Securities Act, in offerings exempt from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act, provided such persons satisfy the Company that they are eligible to participate on such basis. Persons in the United States exercising Subscription Rights to acquire Offer Shares who are permitted to do so in accordance with the foregoing will be required to execute an investor letter in a form acceptable to the Company and the Managers. **Other than persons who are QIBs, no person in the United States may purchase Subscription Rights or otherwise acquire Offer Shares by exercise of Subscription Rights.** The Subscription Rights and the Offer Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, the Hong Kong Special Administrative Region of the People's Republic of China, South Africa or Japan and may not be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, the Hong Kong Special Administrative Region of the People's Republic of China, South Africa or Japan except pursuant to an applicable exemption from applicable securities laws. This Subscription Form does not constitute an offer to sell or a solicitation of an offer to buy Offer Shares in any jurisdiction in which such offer or solicitation is unlawful. Subject to certain exceptions, the Prospectus will not be distributed in the United States, Australia, Canada, the Hong Kong Special Administrative Region of the People's Republic of China, South Africa or Japan. Except as otherwise provided in the Prospectus, the Subscription Rights and the Offer Shares may not be transferred, sold or delivered in the United States, Australia, Canada, the Hong Kong Special Administrative Region of the People's Republic of China, South Africa or Japan. A notification of exercise of Subscription Rights and subscription of Offer Shares in contravention of the above restrictions may be deemed to be invalid.

Execution Only: The Managers will treat the Subscription Form as an execution-only instruction. The Managers is not required to determine whether an investment in the Offer Shares is appropriate or not for the subscriber. Hence, the subscriber will not benefit from the protection of the relevant conduct of business rules in accordance with the Norwegian Securities Trading Act.

Information Exchange: The subscriber acknowledges that, under the Norwegian Securities Trading Act and the Norwegian Financial Undertakings Act and foreign legislation applicable to the Managers, there is a duty of secrecy between the different units of the Managers, as well as between the Managers and other entities in the Managers' groups. This may entail that other employees of the Managers or the Managers' groups may have information that may be relevant to the subscriber, but which the Managers will not have access to in their capacity as Managers for the Rights Issue.

Information Barriers: The Managers are securities firms that offers a broad range of investment services. In order to ensure that assignments undertaken in the Managers' corporate finance department are kept confidential, the Managers' other activities, including analysis and stock broking, are separated from the Managers' corporate finance department by information walls. The subscriber acknowledges that the Managers' analysis and stock broking activity may conflict with the subscriber's interests with regard to transactions of the Shares, including the Offer Shares, as a consequence of such information walls.

VPS Account and Mandatory Anti-Money Laundering Procedures: The Rights Issue is subject to the Norwegian Money Laundering Act No. 23 of 1 June 1 2018 and the Norwegian Money Laundering Regulations No. 1324 of 14 September 2018 (collectively, the "**Anti-Money Laundering Legislation**"). Subscribers who are not registered as existing customers with the Managers must verify their identity to the Managers in accordance with the requirements of the Anti-Money Laundering Legislation, unless an exemption is available. Subscribers who have designated an existing Norwegian bank account and an existing VPS account on the Subscription Form are exempted, unless verification of identity is requested by the Managers. The verification of identity must be completed prior to the end of the Subscription Period. Subscribers that have not completed the required verification of identity may not be allocated Offer Shares. Further, in participating in the Rights Issue, each subscriber must have a VPS account. The VPS account number must be stated on the Subscription Form. VPS accounts can be established with authorised VPS registrars, which can be Norwegian banks, authorised securities brokers in Norway and Norwegian branches of credit institutions established within the European Economic Area (the "**EEA**"). Non-Norwegian investors may, however, use nominee VPS accounts registered in the name of a nominee. The nominee must be authorised by the Financial Supervisory Authority of Norway. Establishment of a VPS account requires verification of identity to the VPS registrar in accordance with the Anti-Money Laundering Legislation.

Personal data: The applicant confirms that it has been provided information regarding the Manager's processing of personal data, and that it is informed that the Managers will process the applicant's personal data in order to manage and carry out the Offering and the application from the applicant, and to comply with statutory requirements.

The data controllers who are responsible for the processing of personal data are the Managers. The processing of personal data is necessary in order to fulfil the application and to meet legal obligations. The Norwegian Securities Trading Act and the Anti-Money Laundering Legislation require that the Managers process and store information about clients and trades, and control and document activities. The applicant's data will be processed confidentially, but if it is necessary in relation to the purposes, the personal data may be shared between the Managers, the company(ies) participating in the offering, with companies within the Managers' groups, the VPS, stock exchanges and/or public authorities. The personal data will be processed as long as necessary for the purposes, and will subsequently be deleted unless there is a statutory duty to keep it.

If the Managers transfer personal data to countries outside the EEA, that have not been approved by the EU Commission, the Managers will make sure the transfer takes place in accordance with the legal mechanisms protecting the personal data, for example the EU Standard Contractual Clauses.

As a data subject, the applicants have several legal rights. This includes inter alia the right to access its personal data, and a right to request that incorrect information is corrected. In certain instances, the applicants will have the right to impose restrictions on the processing or demand that the information is deleted. The applicants may also complain to a supervisory authority if they find that the Managers' processing is in breach of the law. Supplementary information on processing of personal data and the applicants' rights can be found at the Managers' websites.

Terms and Conditions for Payment by Direct Debiting - Securities Trading: Payment by direct debiting is a service the banks in Norway provide in cooperation. In the relationship between the payer and the payer's bank the following standard terms and conditions will apply:

- The service "Payment by direct debiting – securities trading" is supplemented by the account agreement between the payer and the payer's bank, in particular Section C of the account agreement, General terms and conditions for deposit and payment instructions.
- Costs related to the use of "Payment by direct debiting – securities trading" appear from the bank's prevailing price list, account information and/or information given by other appropriate manner. The bank will charge the indicated account for costs incurred.
- The authorisation for direct debiting is signed by the payer and delivered to the beneficiary. The beneficiary will deliver the instructions to its bank who in turn will charge the payer's bank account.
- In case of withdrawal of the authorisation for direct debiting the payer shall address this issue with the beneficiary. Pursuant to the Norwegian Financial Contracts Act, the payer's bank shall assist if the payer withdraws a payment instruction that has not been completed. Such withdrawal may be regarded as a breach of the agreement between the payer and the beneficiary.
- The payer cannot authorise payment of a higher amount than the funds available on the payer's account at the time of payment. The payer's bank will normally perform a verification of available funds prior to the account being charged. If the account has been charged with an amount higher than the funds available, the difference shall immediately be covered by the payer.
- The payer's account will be charged on the indicated date of payment. If the date of payment has not been indicated in the authorisation for direct debiting, the account will be charged as soon as possible after the beneficiary has delivered the instructions to its bank. The charge will not, however, take place after the authorisation has expired as indicated above. Payment will normally be credited the beneficiary's account between one and three working days after the indicated date of payment/delivery.
- If the payer's account is wrongfully charged after direct debiting, the payer's right to repayment of the charged amount will be governed by the account agreement and the Norwegian Financial Contracts Act.

Overdue Payment: Overdue payments will be charged with interest at the applicable rate from time to time under the Norwegian Act on Interest on Overdue Payment of 17 December 1976 No. 100, currently 8.00% per annum as of the date of the Prospectus. If a subscriber fails to comply with the terms of payment, the Offer Shares will, subject to the restrictions in the Norwegian Public Limited Companies Act, not be delivered to such subscriber. The Managers, on behalf of the Company, reserves the right, at the risk and cost of the subscriber, at any time, to cancel the subscription and to re-allocate or otherwise dispose of allocated Offer Shares for which payment is overdue, or, if payment has not been received by the third day after the Payment Date, without further notice sell, assume ownership to or otherwise dispose of the allocated Offer Shares on such terms and in such manner as the Managers may decide in accordance with Norwegian law. The subscriber will remain liable for payment of the subscription amount, together with any interest, costs, charges and expenses accrued and the Managers, on behalf of the Company, may enforce payment for any such amount outstanding in accordance with Norwegian law. The Company and the Managers further reserve the right (but have no obligation) to have the Managers advance the subscription amount on behalf of subscribers who have not paid for the Offer Shares allocated to them within the Payment Date. The non-paying subscribers will remain fully liable for the subscription amount payable for the Offer Shares allocated to them, irrespective of such payment by the Managers.

National Client Identifier and Legal Entity Identifier: In order to participate in the Rights Issue, subscribers will need a global identification code. Physical persons will need a so-called National Client Identifier ("**NCI**") and legal entities will need a so-called Legal Entity Identifier ("**LEI**"). **NCI code for physical persons:** Physical persons will need a NCI code to participate in a financial market transaction, i.e. a global identification code for physical persons. For physical persons with only a Norwegian citizenship, the NCI code is the 11 digit personal ID (Nw: "*fødselsnummer*"). If the person in question has multiple citizenships or another citizenship than Norwegian, another relevant NCI code can be used. Subscribers are encouraged to contact their bank for further information. **LEI code for legal entities:** Legal entities will need a LEI code to participate in a financial market transaction. A LEI code must be obtained from an authorized LEI issuer, and obtaining the code can take some time. Subscribers should obtain a LEI code in time for the subscription. For more information visit www.gleif.org. Further information is also included in Section 11.18 ("**NCI code and LEI number**") of the Securities Note.

Registered office and advisors



Targovax ASA

Vollsveien 19
N-1366 Lysaker
Norway

Managers

Carnegie AS

Fjordalléen 16
N-0250 Oslo
Norway

DNB Markets, a part of DNB Bank ASA

Dronning Eufemias gate 30
N-0191 Oslo
Norway

Legal Advisor to the Company

(as to Norwegian law)

Advokatfirmaet Thommessen AS

Ruseløkkveien 38
N-0251 Oslo
Norway